Archive for the ‘Skin Stem Cells’ Category

Formula One legend Michael Schumacher suffered life-changing head injuries in a skiing accident in 2013 and has since been receiving care at his home in Switzerland. It is believed the record-breaking racing driver cannot walk or stand and may have trouble communicating according to former Ferrari manager Jean Todt. So far Mr Schumachers treatment has been kept private, and nothing has been confirmed officially, however now the racing legend is under the care of world-renowned cardiac surgeon Philippe Menasch.

Mr Menasch is described as a pioneer in cell surgery at his hospital, Georges-Pompidou, in Paris.

According to the NHS: Stem cells are special cells produced by bone marrow (a spongy tissue found in the centre of some bones) that can turn into different types of blood cells.

The cells have been used since the 1980s to grow skin grafts for patients who have suffered life-threatening burns.

Read More:Michael Schumacher health update: Where is Michael Schumacher now?

They are also used in cancer treatments for cancers of the blood, and most recently have been used in repairing damage to the cornea - surface of the eye.

A lot about stem cells is still being discovered, with clinical trials taking place for illnesses and conditions like MS and macular degeneration, heart disease and spinal cord injuries.

The special cells are also being used in neurodegenerative diseases like Parkinsons and Alzheimers and traumatic brain injuries like Mr Schumachers.

In an interview online, Mr Menasch explained stem cell treatment for cardiac conditions is only touching the surface.

Read More:Michael Schumacher could be able to cry and move his thumbs'

He said: Nobody really knows how stem cells are working.

They do not permanently transplant into the myocardium, the muscular tissue of the heart after a couple of days or weeks they just disappear.

Mr Schumacher received stem cell therapy in September in Paris, however, not much information has surfaced about the procedure.

MrMenasch spoke to Italian newspaper La Repubblica and said: There was an explosion in the attention our department received but the situation has already normalised.

Local media dubbed the procedure experimental however MrMenasch denied this saying: everyone is looking for me but I have not used experimental cures.

I do not perform miracles. My team and I are not doing an experiment, an abominable term that is not in line with a serious medical view.

Michael Schumacher is motor racings most successful driver, with a record 91 Grand Prix wins.

He won his first titles with Benetton in 1994 and 1995 followed by five in a row with Ferrari between 2000-2004.

More here:
Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk

The global stem cell therapy market growth has been primarily attributed to the major drivers in this market such as the increasing prevalence of chronic diseases, rising number of clinical trials for cell-based therapy, steady investment, and consolidation in the regenerative medicine market, and favorable regulatory environment.

Get free pdf sample : https://www.marketindustryreports.com/pdf/32

Key Players in the Stem Cell Therapy Market are:

Market Definition: Stem Cell Therapy Market

Stem cells are human cells that have the ability to develop into various cell types such as muscle cells, brain cells they also have the unique ability to repair damaged tissue. Stem cells are divided into two major categories namely: embryonic stem cells and adult stem cells. The embryonic stem cell that is being used to conduct research today came from unused embryos resulting from an in vitro fertilization process which were later donated to science. These embryonic stem cells are pluripotent this basically means that they can turn into more than one type of cell. There are two types of adult stem cells- one of the type comes from fully developed tissues, such as the brain, the skin, and even bone marrow. The second type is induced pluripotent stem cells. These are adult stem cells that have been manipulated in a laboratory to take on characteristic of embryonic stem cells which enables them to turn into more than one type of cell.

The worldwide Stem Cell Therapy Market report give point by point data about the Stem Cell Therapy Market with a fitting examination of a few parameters and patterns impacting its advancement at a worldwide premise.

Scope of the Market :

The stem cell therapy market research provides a holistic view of the stem cell therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products allied with the therapeutic application of stem cells. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global stem cell therapy market.

Market Segmentation

Market drivers: Stem Cell Therapy Market

Market Restraints: Stem Cell Therapy Market

Key Developments: CRISPR Technology Market

Stem cell therapy is accelerating at a huge growth circle that promises a potential for diversified career opportunities.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Table of Contents

INTRODUCTION

RESEARCH METHODOLOGY

In light of the examination of affecting development and constraining parameters, the exact information showing the future development pattern of the market can be gotten, which is altogether clarified in the Stem Cell Therapy Market research report. The data with respect to the moving toward circumstances that can help the market capitalization is additionally incorporated into the report. The report likewise involves fundamental data, for example, yearly income age, advertise esteem, use, yearly deals, and other significant measurable information, with respect to the key market contenders which incorporate a few associations, firms, item makers, sellers, and wholesalers.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Read More About Report Click Here:

About Us

Market Industry Reports is a global leader in market measurement and advisory services. It is 100% subsidiary of Maniks Systems Pvt Ltd. The firm has always been at the forefront of innovation to address the worldwide industry trends and opportunities.

Contact Us-

2nd Floor, Manikchand Ikon,

B-Wing, Dhole Patil Road,

Sangamwadi, Pune 411 001

Email: [emailprotected]Phone: +1 347 767 5477 ( US )+ 91 8956 767 535 ( IN )Website: https://www.marketindustryreports.com/Follow Us- LinkedIn | Twitter | Facebook

See the rest here:
Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research

Dr. Mansour identifies two defining properties of stem cells: First, they can self-regenerate, meaning they divide and give rise to more regenerative cells of the same kind. Second, stem cells can mature or differentiate into specialized cells which carry out a specific function in the skin, muscle, or blood.

A major breakthrough in modern medicine revolves around the use of Umbilical Cord Stem cells. These powerful cells are injected into damaged tissues, ligaments, muscles and tendons, arthritic joints, or other tissues in an attempt to stimulate and accelerate healing.

Regenerative Medicine from Umbilical Cord Stem Cells in Macomb County

We were the first clinic in Michigan to offer umbilical cord stem cell injections as a holistic alternative to pain management and cell regeneration.

Dr. Mansour conducts monthly educational seminars and offers free one on one consultation, during which he reviews all imaging studies to determine if the patient is a candidate for stem cell therapy. For those who qualify, he offers a customized plan that is specific to each patient.

There is a wide range of conditions which may be treated with stem cells, including:

Joint Pain

Arthritis

Ligament Tears

Cartilage Tears

Meniscus Tears

Nerve Damage

Back Pain

And So Much More!

A Better Approach with Revolution Wellness

Are you suffering from constant discomfort, or diagnosed with a specific condition only to be told that medication or surgery are your only options? At Revolution Wellness, we believe otherwise. We use the innovative technology of stem cell therapy to treat discomfort and serious physical ailments.

Call our office today for more information about how we can get you on your way to living with less pain!

Read more:
Health Repair Damaged or Diseased Tissue with Stem Cell Injections 10:38 AM, Sep 28, 2019 - WXYZ

At 34, Noveel Pandya is an aspiring billionaire who has made it big right here in the UAE. Image Credit: Atiq Ur Rehman/Gulf News

Dubai: At 34, Noveel Pandya is a billionaire who has made it big right here in the UAE. While it would bealright to say he is more blessed than others his father, Narendra Pandya, ran an established business in the UAE before Noveel started Noveel is attempting to makea mark withhis own venture,Bioscience Clinic Middle East.

Senior Pandya runs a successful business House of Chemicals (HOC) - as a distributor of specialty and commodity chemicals for key suppliers especially in businesses such as oil drilling, refineries, gas plants, lubricant plants, water treatment for desalination plants and sewage treatment.

Pandya,Noveels father,also started another company BDH with an expertise in supply, installation, commissioning and maintenance of all laboratory equipment and furniture.

We are pretty much the turnkey laboratory projects expert, said Noveel, in an interview with Gulf News at his house in Emirates Hills.

But Noveels babyBioscience Clinic Middle East a center offering regenerative medicine and personalised autologous cell therapies brings him much pride and cheer. Premium services of the company include cryopreservation and expansion of cells used for anti-aging treatments, aesthetic and plastic surgery, wound care and for dermatological imperfections.

Starting from the bottom up

With a family-run business, it was perhaps a given for Noveel to become a businessman himself and run his fathers mantle.

But this was not achievedbefore he had to work his way up to the top.

In fact I started from bottom low. There was no way my father was going to have me take over peoples jobs in the company who had put in years of hard work. So there was a huge process of learning one that taught me humility and gratitude for the people who are part of our team, he said.

Noveels father came to work in the UAE in the early 70s. He said, From the stories I hear from him - there were many challenges and struggles he faced. In fact, lots of people who came with him to work in the UAE returned home.

It wasn't handed on a platter

Before jumping to the conclusion that he had it all easy,Noveel had to prove his capabilities just like any employee of the firm and had to work his way up the ladder.

There was no way my father was going to let me work above all those people who had put in so many years of service. From 2007 until 2011 it was all about learning and observation.

Take this: From the time Noveel completed his MBA in London in 2011 to join the family, he has helped the family business grow by a 100 per cent year on year.

Noveel said, BDH for example was making Dh35 million in 2007, but today, it is making over Dh140 million.

As for his own venture, there is massive potential for Bioscience Clinic Middle East as the stem cell venture business for the MENA region is tipped to be around $2 billion.

According to a report published in April 2019, the global stem cell market size is expected to reach $15.63 billion by 2025.

Today, we have little competition in the MENA region, so as you can see, there is a massive potential to grow.

Reverse-aging with stem cell therapy

Noveel said typically a client would reach out to a clinic to undergo a full scan and evaluation. A consultation with specialised doctors follows. Once the evaluation is done and the patient passes the test to become a candidate for the stem cell venture project, the doctor executes a plan to extract fat from the persons body.

This fat stores stem cells and we extract it from the fat. We have advanced technology in place to do the job for this. The stem cells derived are stored in vials and frozen, he explained.

The stem cells are multiplied to a couple of hundred million or sometimes a billion in order to produce the required volume.

Noveel said: When the stem cells are frozen they stop the ageing process of the cells. This means it effectively helps reverse-age a person. If someone at the age of 30 comes to us and asks us to freeze their cells. We do it. The person can always come back ten or 15 years later to rejuvenate their skin, hair or any part of their body.

"Just imagine at 45 or 50, this person wants to rejuvenate their skin. What we will do is inject their cells which were frozen when they were 30. When these cells are injected, they will leave the person with a skin looking as young as 30.

Stem cell therapy is said to be the most natural way to rejuvenate your skin, body and cells. The concept is called autologous which means it is your own cells which go into your body - not that of siblings or parents. Basically it is your own cells which are injected to the body and it is the most natural way to rejuvenate your body and skin.

How long does it take for the body to rejuvenate?

It depends on the body type, the persons lifestyle, food habits and more. This can take from a couple of weeks to a whole month. Remember, this is not an overnight fix. In fact treatments that come with overnight fixes can be very dangerous. Anything that has a drastic effect on your body is not good at all, explained Noveel.

We have seen fine lines or wrinkles disappearing in seven to 15 days after the cells were injected. The effect of the cell injected can last up to a year or over a year. But it all depends on the body type. Remember, your body can never reject your own cells it always accepts its cells.

Our clients are people from the age 18 and above. People who use alternative treatments come to us. I had a 63-year-old man come in from India saying they wanted their stem cells extracted.

Screening process

When a person comes there is a screening process that goes in. Upon successfully passing the screening process, other factors expel candidates like those who are typically heavy smokers or people with certain existing medical conditions.

If a client has a virus present in the body, that would drastically effect the quality of cells. If the quality of cells we get right in the beginning is poor the effect will not be desirable for them. Similarly, if the person is diagnosed with some STDs, certain terminal illness, we do not recommend them to store their cells.

Package cost

An initial package offered by Bioscience Clinic Middle East is close to Dh15,000 which includes a consultation, cell extraction, one year storage of stem cells and application. The application can be used anytime. One is not forced to use it immediately.

We are the only business in the region offering such services, Noveel claimed.

Business investment

Noveel said he invested 5 million euros in Bioscience Clinic Middle East.

This money went in for the facilitation of the lab, the treatment, and consultation, hiring skilled professionals and setting up class clean rooms for storing stem cells. Remember we are talking about a niche industry and a very niche product. The investment is for this.

Challenges as a millennial

There is a definite need to make an effort to be heard. Sometimes we are not taken seriously and that is the only challenge I see for myself today. But never give up. Keep dreaming and have the zest to grow. Patience is a virtue that we millennials need to build. Success does not come overnight. For example, my break-even did not happen for long. But I kept at my dreams and went after my goals. This is critical, Noveel said

Here is the original post:
Meet Noveel Pandya: Indian multi-millionaire whose stem cell venture project is the talk of town - Gulf News

When it comes to establishing a skincare routine, its not always straight forward. Long gone are the days of simply cleansing, toning and moisturising. We often hear words like peptides, retinol, vitamin C, acids and serums. But what do they all mean? But more importantly which product goes first?

One rule of thumb to guide you is to apply skincare products in order of their consistency, the thinnest first finishing with the thickest. But, its not just about knowing which order to apply them, its also important to know what products you need to use and how often to use them.

According to Dr Anita Sturnham, who specialises in dermatology, our skin has a 24-hour circadian rhythm, meaning that its anatomical and physiological needs change from AM to PM. In the day your skin needs protection from external factors like sunlight and pollution, in the evening its repairing itself. Which is why you need different products for different times of the day.

Its also important not to mix certain ingredients like exfoliating treatments and vitamin C together, otherwise they can counteract one and other.

Confused much?

To save you some serious head scratching, we have put together this clear, step by step guide on which order to apply your skincare products to take out the guess work for you.

AM routine:

As youve removed your makeup the night before, begin by using a light cleanser to clear the remnants of any skincare products or excess oils left on the skin. Your morning cleanser should be gentle, hydrating and non-abrasive.

Shop now Glossier Milky Jelly Cleanser, Glossier.com, 15

Shop now CeraVe SA Smoothing Cleanser, Feelunique.com, 12

Shop now L'Occitane Gel-To-Foam Cleanser, Debenhams.com, 19

Shop now La Roche-Posay Toleriane Dermo-Cleanser, Feelunique.com, 12.50

Next, use a water-based toner to help rebalance the skins PH levels and prepare your skin for your serum and moisturiser.

Shop now Dr Barbara Sturm Balancing Toner, Cultbeauty.co.uk, 45

Shop now Neal's Yard Rejuvenating Frankincense Toner, Feelunique.com, 20

Shop now Fresh Rose Deep Hydration Facial Toner, Cultbeauty.co.uk, 21

Shop now Caudale Beauty Elixir, Lookfantastic.com, 12

Follow by using an eye cream. Its important to use a separate eye cream because the skin around the eye area is a lot thinner and more sensitive than the rest of face. This is why its more prone to ageing over time, so using a hydrating eye cream rich in ingredients like hyaluronic acid and peptides help to boost collagen levels in the under eye area.

Shop now Vichy Minral 89 Eyes, Feelunique.com, 20

Shop now Clinique Moisture Surge Eye Concentrate, Lookfantastic.com, 27.50

Shop now Avne Soothing Eye Contour Cream, Lookfantastic.com, 9.50

Shop now Drunk Elephant C-Tango Multivitamin Eye Cream, Cultbeauty.co.uk, 54

Hyaluronic Acid is a key skincare ingredient which can be used by all skin types, according to Dr Sturnham: hyaluronic acid helps to provide structure to our cells and supports our skins hydration barriers. This extra hydration therefore helps to plump to the skin, minimising the appearance of fine lines.

In order to reap the maximum benefits, Dr Sturnham recommends applying hyaluronic acid in small layers throughout your morning and evening skincare routine, as well as using as a separate serum.

Shop now The Ordinary Hyaluronic Acid 2% + B5, Lookfantastic.com, 5.90

Shop now SkinCeuticals H.A. Intensifier, Lookfantastic.com, 85

Shop now Evolve Organic Beauty Hyaluronic Serum, Feelunique.com, 12

Shop now The Inkey List Hyaluronic Acid, Feelunique.com, 5.99

A serum is designed to penetrate the deeper dermal layers of your skin and nourish it with a variety of skin protective ingredients. Layering serums can also be effective to adapt your skincare routine to your specific skin needs.

Dr Sturnham recommends layering serums that have these key ingredients to promote healthy skin throughout the day:

Vitamin C - Vitamin C is an essential nutrient rich ingredient that should be used daily in your skincare routine. Our skin has built in receptors for Vitamin C says Dr Sturnham, which is why it is key to ensure we get our daily skincare fix of it. Vitamin C has many benefits such as improving skin tone, protecting the skin against pollution and UV damage, boosting cell repair and giving the skin a radiant look.

Panthenol (Vitamin B5) - Panthenol otherwise known as Vitamin B5 is an ingredient that helps to soften and soothe the skin by helping (repetition of skin) protect against irritation and water loss.

Ferulic Acid - Ferulic Acid is an antioxidant which helps to boost the effects of other antioxidants used in serums. It also helps to reduce signs of ageing like fine lines and wrinkles.

Shop now Decree Peptide Veil +, Cultbeauty.co.uk, 115

Shop now Paula's Choice C15 Super Booster, Lookfantastic.com, 46

Shop now Medik8 Hydr8 B5, Facethefuture.com, 32

Shop now The Ordinary Vitamin C Suspension 23% + HA Spheres 2%, Cultbeauty.co.uk, 4.90

Once you have applied your serum and given it time to absorb into the skin, it is then time to apply a moisturiser. This helps to hydrate your skin throughout the day and creates a smooth base for makeup. Dr Sturnham recommends non pore-clogging ingredients like safflower, apricot kernel and squalene.

Shop now Kate Somerville Goat Milk, Cultbeauty.co.uk, 55

Shop now Clinique Dramatically Different Hydrating Jelly, Feelunique.com, 31

Shop now Glossier Priming Moisturiser, Glossier.com, 18

Finish by using an SPF (Sun Protection Factor) to protect your skin against UV damage. UV damage causes signs of premature ageing such as wrinkling and pigmentation. Experts recommend using an SPF30 or higher on your face to deliver optimum UV protection.

Shop now REN Clean Screen Mineral SPF 30, Lookfantastic.com, 30

Shop now Kiehl's Ultra Light Daily UV Defense, Feelunique.com, 28

Shop now Vichy Ideal Soleil Mattifying Face Fluid Dry Touch SPF30, Feelunique.com. 16.50

Shop now SkinCeuticals Ultra Facial Defense SPF50+, Lookfantastic.com, 37

PM routine

For your evening cleanser use something with more active ingredients that has an exfoliation to it and that is deep pore cleansing. If you are wearing makeup and SPF during the day, we recommend double cleansing: using a balm or oil based cleanser first to breakdown the makeup and excess oil and following with a gentle, hydrating gel cleanser.

Shop now Emma Hardie Amazing Face Moringa Cleansing Balm, Lookfantastic.com, 47

Shop now The Body Shop Oils of Life Cleansing Oil-in-Gel, Thebodyshop.com, 12

Shop now Decree Deep Cleanse, Cultbeauty.co.uk, 55

Shop now DHC Deep Cleansing Oil, Feelunique.com, 11

Once again follow with a toner to balance your skins PH levels and prep your skin for your serum and moisturiser. You can also opt to use an acid toner two to three times a week depending on your skin type. Look for ingredients like glycolic acid, lactic acid and mandelic acid which will exfoliate the skin and even texture.

Shop now Dr Dennis Gross Alpha Beta Ultra Gentle Daily Peel, Lookfantastic.com, 87

Shop now Pixi Glow Tonic, Lookfantastic.com, 18

Shop now Nip & Fab Glycolic Fix Daily Cleansing Pads, Lookfantastic.com, 12.95

Shop now Paula's Choice 2% BHA Liquid Exfoliant, Lookfantastic.com, 28

If you are really invested in fighting signs of ageing and those pesky fine lines, retinol is the way to go. Otherwise known as vitamin A, retinol is a rich ingredient which helps to fight signs of ageing at a deep cellular level. It helps to promote the production of collagen and elastin, reduce pore congestion, regulate the production of sebum and work against inflammation.

There are many options for retinol on the market, but Dr Sternham recommends using retinol into your skincare routine in the form of a serum. Look for words like: granactive Retinoid or hydroxypinacolone retinoate which are less harsh on the skin.

Use it in small doses every night after cleansing and toning before applying your moisturiser and built up gradually. Make sure that you always use an SPF in your morning routine, as retinol will make your skin more photosensitive.

Shop now Medik8 Crystal Retinal 1, Facethefuture.com, 39

Shop now Elizabeth Arden Retinol Ceramide Capsules, Lookfantastic.com, 42

Shop now Drunk Elephant A-Passioni Retinol Cream, Cultbeauty.co.uk, 62

Shop now Disciple Dreamy Skin, Cultbeauty.co.uk, 35

Like your AM routine, follow up with an eye cream to the orbital bone area. We recommend saving yourself some money and opting for the same one morning and night.

Add a serum to your PM skincare routine like you would before a moisturiser in the day. Dr Sturnham advises to look for ingredients that support your skins physiological needs at night. Pay attention to how your skin is feeling, is your skin dry? Is it showing signs of pigmentation? Is your skin feeling congested? Look for serums that will address the particular needs of your skin and that ideally have a variety of skin benefiting ingredients. Dr Sturnham recommends ingredients like alpha arbutin, hyaluronic acid and plant-based stem cells.

Shop now Kate Somerville KX Active Concentrates Ceramides & Omegas, Spacenk.com, 84

Shop now Bybi Supercharge Serum, Feelunique.com, 32

Shop now The Ordinary Alpha Arbutin 2& + HA, Cultbeauty.co.uk, 7

Shop now Glossier Super Bounce, Glossier.com, 24

For your evening moisturiser use one with a slightly richer, thicker consistency than you would during the day to hydrate dehydrated skin.

Shop now Trilogy Replenishing Night Cream, Lookfantastic.com, 32.50

Shop now Herbivore Moon Fruit Night Treatment, Cultbeauty.co.uk, 48

Shop now CeraVe Moisturising Lotion, Lookfantastic.com, 9

Always Remember

-Avoid using exfoliating or foaming cleansers followed by alcohol-based toners, as this will dry out skin, making it prone to sensitivity.

-Take your time to apply each product, allow each layer to absorb into the skin before applying the next one.

-Use your treatment products in order of their consistency from lightest to thickness.

-Avoid mixing water-based and oil-based products in your same skincare regime.

-Keep your cleansing routine simple on a daily basis and reserve the more intensive exfoliation routine for once a week.

-Avoid using intensive exfoliators with Vitamin C.

Follow Emily on Instagram.

Originally posted here:
This is the correct order to apply your skincare products - cosmopolitan.com

Scroll To See More Images

Its safe to say that we are in a total German state of mind lately. And now that Oktoberfest is here, we are more than appreciative of the delicious international fare the season always brings. However, wed be foolish not to reflect on the awesomeness that is German beauty brands this month, especially since it seems to be having a major moment in 2019.

And while you may be trying to picture just how G-Beauty could ever dethrone the beauty behemoth that is K-Beauty, Martina Joseph, CEO of German brand Dr. Hauschka USA, explains that the German beauty scene is here to stay, especially since it has a strong emphasis on high-quality products and standards. Germany has a brilliant reputation for quality products and quality standards, says Joseph. The consumer is recognizing the value proposition of clean ingredients, and are seeking clean, sustainable, and responsible products.

And clean beauty factor aside, theres no denying that G-beauty is also popular due to its kind international appeal. Besides, we all know how popular French girl beauty still is to this day. To help you say hallo to the best German beauty brands, we rounded up nine skincare and makeup companies worth keeping on your radar. From drugstore-favorites to luxurious brands worth investing in, check out our top brand picks just in time for Oktoberfest below.

Dr. Hauschka may have an impressive roster of celebrity fans (including starlets like Anne Hathaway and Julia Roberts) to brag about, but its definitely for good reason, as this German skin-care brand utilizes natural ingredients to help improve the performance of your skin.

And aside from the cleansing, moisturizing, and nighttime needs the brand offers, its worth mentioning that Dr. Hauschkas toning products are equally exceptional. Dr. Hauschkas original facial toner, for example, is nothing short of a skin-care superstar, as it utilizes a potent blend of anthyllis and witch hazel extracts to gently clarify the skin.

$37 at Dermstore

Created by German dermatologist Dr. Tim Golueke, this luxurious line of anti-aging products has already found some firm footing in the states, as its currently sold at retailers like Bergdorf Goodman. But, dont let its hefty price tag fool you into thinking its just another cash grab, as this revolutionary brand utilizes unique ingredient Royal Fern (an extremely moisturizing evergreen plant thats also resistant to environmental influences) to combat skin aging on all levels.

The brands anti-aging anti-aging serum definitely uses a special Royal Fern Complex (plus hyaluronic acid and vitamin C from Acerola cherry) to protect the skin against genetic and environmental stress, making it a must for those who are looking to add an anti-aging alternative to retinol to their routine.

$295 at Violet Grey

This German skin-care brand is definitely a clean beauty enthusiasts dream, as each product contains minimally processed ingredients that dont contain preservatives, solvents, and surfactants. And while we are very impressed by Less amazing line of hairbrushes, theres no denying that the brands skin-care essentials are a must-see.

The Less Face Oil for Dry Skin, is one of the products we cant stop talking about, as it utilizes a blend of avocado, jojoba, and apricot oils for supple and moisturized skin.

$72 at Less

Seoul isnt the only authority on sheet masks now that this German skin-care brand has entered the fold, as it also delivers budget-friendly products that address all your skin woes. And sheet masks aside, Magicstripes has also unveiled some eye-raising products that have garnered media here in the United States. The brands eyelid lifting strips, for example, have been featured in outlets like Allure, making it something to see for yourself, should you be curious.

However, if sheet masks are practically your main squeeze, you really cant go wrong with this hyaluronic acid-infused product, as it leaves your skin feeling oh-so-hydrated in a matter of minutes.

$15.52 at MagicStripes

Combining revolutionary science with biological wisdom, this line of products was developed by German-born professor Augustinus Bader, who is globally recognized as one of the leading voices in regenerative medicine. And what makes this line of products unique is the innovative science behind it, as professor Bader studied how to perfect the skins healing process for up to 30 years. This same research ultimately led him to discover how to unlock the signals that trigger ones own stem cells.

Professor Bader initially applied his research to develop a special wound gel for severe burn victims. However, since the gel delivered remarkable results, it then inspired a full line of skin and body products to support the skins natural healing process. The anti-aging Augustinus Bader Body Cream is definitely one of the major highlights of this skin-care collection, as it drenches dehydrated skin in essential moisture.

$165 at Augustinus Bader

Hailing all the way from Frankfurt, this German beauty brand boasts an impressive line of high-quality brushes, palettes, lipsticks, and foundation products. However, you dont have to be based in Germany to score ZOEVA products, as the brands Authentik Skin Foundation is set to debut at Ulta later this month.

And unlike some drying foundations on this market, expect this rosehip oil-infused product to leave your skin feeling silky smooth upon application.

$28 at Ulta

NIVEA surprisingly has some strong German roots, as the brand was founded in 1882 by German physicist Paul Carl Beiserdorf. And while NIVEA products are definitely found abroad, youll love to know that they are pretty easy to find here in the states as well.

Drugstores like CVS and Walgreens, for example, actively carry Nivea products, making them an absolute must if you are looking to give your skin the TLC it deserves.But, if you are a newbie to the brand, we strongly recommend investing in the brands highly moisturizing cucumber body wash.

$6.49 at CVS

Founded by German aesthetics doctor, this sophisticated line of skin-care products (think creams, serums, and facial scrubs) has gained quite the celebrity fanbase. However, starpower isnt the only thing thats driving Dr. Barbara Sturms popularity onward and upward, as its innovative ingredient science is also worth buzzing about.

Apart of that science includes focusing on utilizing unique and powerful ingredients, as the brands full skincare range utilizes Purslane, an anti-aging powerhouse that helps calm down inflammation. If you are extra curious about adding Purslane to your routine, trust that Dr. Sturms new Skin Food supplement definitely uses this superstar ingredient (plus other skin-boosting antioxidants!) to help rehabilitate and protect your complexion.

$95 at Sephora

This affordable beauty brand also has some German roots, as its earliest origins stem back to 2004, when it was founded by Christina Oster-Daum. Flashforward to 2019, and its safe to say that Catrice has become nothing short of a global sensation, as its line of affordable makeup products can easily be found at American beauty retailers like Ulta.

Catrices HD Liquid Coverage Foundation surely is a product to consider if you are looking for affordable foundations, as it retails for just $10.99, and delivers long-lasting coverage.

$10.99 at Ulta

Our mission at STYLECASTER is to bring style to the people, and we only feature products we think youll love as much as we do. Please note that if you purchase something by clicking on a link within this story, we may receive a small commission of the sale.

Read more here:
German Beauty Brands to Try This Oktoberfest and Beyond - STYLECASTER

KEY POINTS

Although graft-versus-host disease is a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation, involvement of the central nervous system in this disease is uncommon.

In patients with a previous hematopoietic stem cell transplantation presenting with neurologic manifestations, central nervous system graft-versus-host disease should be on the differential diagnosis.

Diagnosis of central nervous system graft-versus-host disease relies on exclusion of other infectious, autoimmune, vascular, drug-related and paraneoplastic processes, along with compatible imaging and histopathologic findings.

The primary treatment of central nervous system graft-versus-host disease is immunosuppression with high-dose corticosteroids.

A 68-year-old man presented to the emergency department with a 1-week history of sudden-onset myoclonus of his right leg. His medical history included allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome performed 742 days earlier, type 2 diabetes mellitus, hypertension and dyslipidemia. The patient had undergone a 9/10 unrelated human leukocyte antigen (HLA) donor transplantation, and after transplantation, his myelodysplastic syndrome was in complete remission and he had complete donor engraftment. On presentation, he was receiving methotrexate (10 mg by mouth weekly) for large granular lymphocytosis and acyclovir (400 mg by mouth twice daily) for herpes simplex virus prophylaxis. A detailed neurologic examination on presentation showed a right-sided pyramidal distribution of weakness and a stimulus-sensitive, spontaneous positive myoclonus, present in the right leg more than the arm, and absent in the face. Deep tendon reflexes were brisk on the right side.

Given this patients history of hematopoietic stem cell transplantation and relative immunosuppression with methotrexate, the differential diagnosis was broad and included central nervous system infections, central nervous system relapse of his primary malignancy, metabolic derangements, paraneoplastic process, microangiopathy, central nervous system vasculitis, toxicity related to immunosuppressive agents, and central nervous system graft-versus-host disease. On further history, it was noted that he received a reduced intensity conditioning transplantation with fludarabine, busulfan and total body irradiation of 200 Gy. His graft-versus-host disease prophylaxis was with anti-thymocyte globulin, and posttransplantation cyclophosphamide and cyclosporine.1

The patient was admitted to the internal medicine service, and neurology was consulted, given his neurologic findings. Magnetic resonance imaging (MRI) of the brain showed multiple scattered T2-weighted fluid-attenuated inversion recovery hyperintense, non-enhancing, mildly expansile, cortical and subcortical lesions in both cerebral hemispheres, with no associated restricted diffusion (Figure 1AD).

Axial magnetic resonance imaging of the brain in a 68-year-old man with myoclonus after allogeneic hematopoietic stem cell transplantation. Pretreatment (A) T2-weighted fluid-attenuated inversion recovery (FLAIR), (B) T1-weighted postgadolinium, (C) diffusion-weighted and (D) apparent diffusion coefficient mapping images showing multiple scattered cortical and subcortical non-enhancing T2 and FLAIR hyperintense lesions (arrowheads) throughout the supratentorial brain. The lesions did not show restricted diffusion by diffusion-weighted imaging and apparent diffusion coefficient mapping. Posttreatment with corticosteroids, (E) T2-weighted FLAIR, (F) T1-weighted postgadolinium, (G) diffusion-weighted and (H) apparent diffusion coefficient mapping images show resolution of lesions.

Over the following days, the patient had a rapid neurologic deterioration. He became nonverbal, and his only preserved motor function was smooth pursuit eye movements. Given this rapid progressive encephalopathy, the patient was treated empirically for viral encephalitis with acyclovir (800 mg intravenously every 8 hours). Despite this treatment, the patients clinical condition did not improve. Lumbar puncture showed a protein level of 0.53 (normal 0.20.45) g/L, a glucose level of 3.7 (normal 2.54.5) mmol/L and no pleocytosis. Microbiological and molecular analysis did not show any evidence of causative infectious pathogens; the analysis included an extensive panel of bacterial, viral (EpsteinBarr virus, cytomegalovirus, polyomavirus, varicella zoster, herpes simplex, human herpesvirus 6, rubella, measles, West Nile virus and arbovirus), parasitic (toxoplasmosis), prion (CreutzfeldtJakob disease) and fungal (Cryptococcus) infections. Electroencephalography showed diffuse slow wave activity corresponding to nonspecific encephalopathy but did not show any epileptogenic focus. There was no evidence of malignant cells on cerebrospinal fluid cytopathology and flow cytometry. A vasculitis panel including cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), perinuclear ANCA (p-ANCA), antinuclear antibodies, anti-double stranded DNA, C3, and C4 was negative. Testing for antibodies for paraneoplastic syndrome was negative. Methotrexate-induced leukoencephalopathy, classically seen in patients receiving high-dose methotrexate, especially intrathecally, was included in the differential diagnosis. However, the patients MRI findings were inconsistent owing to sparing of the centrum semiovale, as well as a lack of restricted diffusion.2 Furthermore, his symptoms persisted despite discontinuation of methotrexate.

Given worsening of the patients clinical condition and radiographic findings despite 10 days of treatment with intravenous acyclovir, a brain biopsy of the left frontal parietal cortical lesion involving both grey and white matter was performed. This showed perivascular lymphocytic infiltrate (Figure 2A). Luxol fast blue stains showed the absence of demyelination (Figure 2B). There was evidence of microglial activation involving the neuropil and perivascular spaces, highlighted by CD163 immunostains (Figure 2C). A sparse CD3 positive T lymphocyte perivascular infiltrate was present, without direct infiltration of the vessel wall (Figure 2D). There were no CD20 positive B lymphocytes. The pathologic findings of perivascular infiltrate were consistent with literature reports of central nervous system graft-versus-host disease. Investigations looking for other sites of involvement including liver enzymes, cutaneous examination and endoscopy, although not exhaustive, did not show graft-versus-host disease of other organs.

Histopathologic images of the patients frontal cortex biopsy. (A) Hematoxylin and eosin staining showing sparse perivascular lymphocytic infiltrate in the white matter (arrowheads). (B) Luxol fast blue staining showing the absence of demyelination. (C) Perivascular activated microglia as shown by CD163 staining (arrowheads). (D) T lymphocytes infiltrating perivascular spaces (black arrowhead) and the neuropil (green arrowhead) as shown by CD3 staining. Scale bar = 200 m.

Even with this extensive workup, the patients diagnosis was unclear. It was imperative that infectious causes were considered and ruled out, which we had done. Given the patients clinical deterioration, a presumptive diagnosis of central nervous system graft-versus-host disease was made, and an empirical course of corticosteroid pulse was started (methylprednisolone 150 mg/d intravenously). Clinical improvement was rapid, and by day 3 of corticosteroid therapy, the patient was able to move his limbs and vocalize. He continued to improve and was ambulatory within 2 weeks of treatment. Repeat MRI showed resolution of many of the lesions (Figure 1EH). The patients dosage was subsequently tapered, and he was transitioned to maintenance prednisone (60 mg/d by mouth) and azathioprine (75 mg/d by mouth).

Unfortunately, recurrent infections developed while the patient was receiving immunosuppressive treatment. Three months later, as his prednisone was tapered, he again had a flare of neurologic symptoms, and MRI showed worsening of the lesions. The patients goals of care were changed to comfort measures, and he died 927 days after the transplantation and around 195 days after onset of the central nervous system symptoms.

Allogeneic hematopoietic stem cell transplantation is a life-saving treatment for many hematologic diseases. Graft-versus-host disease is a leading cause of morbidity and mortality after allogenic hematopoietic stem cell transplantation.3 Between 30% and 50% of patients will develop graft-versus-host disease, whereby the donated tissue (the graft) recognizes the recipient (the host) as foreign and mounts a T cellmediated immune response.4 The clinical manifestations vary, as multiple organs can be affected.

Classification of graft-versus-host disease has traditionally been divided into acute and chronic, depending on the onset of symptoms within or beyond 100 days, respectively. However, recent criteria consider overlap syndromes with increased emphasis on clinical features rather than timing of symptom onset alone.5,6 Central nervous system graft-versus-host disease is a rare but emerging entity after allogeneic hematopoietic stem cell transplantation, probably in part because the number of hematopoietic stem cell transplantations has risen.79

Although chronic graft-versus-host disease can affect any organ, the skin, gastrointestinal tract, liver, joints, fascia and lungs are most frequently affected. Signs and symptoms of graft-versus-host disease relate to the organs of involvement, including maculopapular rash, hyperbilirubinemia with jaundice, and abdominal pain with either nausea and vomiting or diarrhea.4 With such broad-ranging clinical features, diagnosis relies on the assessment of target organs by means of clinical, laboratory and pathological findings. Important risk factors include compatibility of recipient and donor, including degree of HLA mismatch, sex of donor and recipient, use of peripheral-blood stem cell grafts and the conditioning regimen used. Criteria from the National Institutes of Health (NIH) help in defining and stratifying chronic graft-versus-host disease.10 Because of the rarity of cases, central nervous system graft-versus-host disease is not defined in the NIH criteria.

Neurologic involvement (first documented nearly 3 decades ago11) is rare, and graft-versus-host disease afflicting both the central and peripheral nervous system has been described in the literature.79 Symptoms involving the central nervous system are often nonspecific and can include headaches, altered mental status, seizures and paresis.

In a recent case report and review, Ruggiu and colleagues reported a total of 39 presumed cases of central nervous system graft-versus-host disease, with a median patient age of 35 (range 0.6768) years and a median duration of symptomatic presentation of 385 (range 77320) days after transplant.8 In this case series, which is limited by a lack of histopathology in more than half of the patients, those presenting with central nervous system disease without other chronic features of graft-versus-host disease presented earlier and in most cases had a history of acute graft-versus-host disease.8

Our patient did not present with evidence of extracentral nervous system graft-versus-host disease. This may be owing to the newer conditioning regimen he was given, immunosuppression, or other underlying medical diagnoses and comorbidities. Our current lack of understanding of the clinical course of patients with central nervous system graft-versus-host disease highlights the importance of further research into identifying risk factors, developing better diagnostic tools and finding new strategies for prevention.

The diagnosis of central nervous system graft-versus-host disease is complicated by conflicting differential diagnoses that can be challenging to exclude, such as infection, drug and radiation toxicity, and primary disease metastasis. As such, a combination of microbiologic and laboratory studies, and radiographic and histopathologic findings are required for the workup.

Given these diagnostic challenges, the 2009 Consensus Conference on Clinical Practice in chronic graft-versus-host disease defined the neurologic manifestations of the disease.5 This definition included the following criteria: 1) occurrence with chronic graft-versus-host disease affecting other organs, 2) neurologic signs of central nervous system involvement without other explanation, 3) corresponding MRI brain abnormality, 4) abnormal cerebrospinal fluid findings, 5) brain biopsy or postmortem examination confirming graft-versus-host disease and 6) response to immunosuppressive therapy.5 Criteria 1 and 2 are considered mandatory requirements in the diagnosis of central nervous system graft-versus-host disease, whereas criteria 36 are facultative requirements. A definitive diagnosis can be made when all 6 criteria are met, and a possible diagnosis can be made when both mandatory criteria and at least 2 facultative requirements are met.

Our patient met all the criteria according to this consensus definition except the first (occurrence with chronic graft-versus-host disease affecting other organs). Interestingly, the case series by Ruggiu and colleagues showed that 28% of patients did not have extracentral nervous system features of chronic graft-versus-host disease, although most of these patients did have a history of extracentral nervous system acute graft-versus-host disease.8

Despite immunosuppressive treatment, central nervous system graft-versus-host disease portends a poor prognosis. Prior case series show that even though 70% of patients who received treatment with corticosteroids showed at least a partial response, only 18% of patients were alive at last follow-up.8

This case highlights the importance of the late central nervous system complications of hematopoietic stem cell transplantation, the challenges with diagnosis and the role of timely immunosuppressive therapy. Though concepts regarding central nervous system graft-versus-host disease continue to evolve, it is important to keep as a differential diagnosis in patients with noninfectious neurologic complications who have undergone hematopoietic stem cell transplantation.

The authors acknowledge the contributions of Russell Yanofsky, Sunu Cyriac, David G. Munoz and Auro Viswabandya.

Competing interests: None declared.

This article has been peer reviewed.

The authors have obtained patient consent.

Contributors: The authors all contributed substantially to the conception of this work, including acquisition, analysis and interpretation of raw patient data in the form of clinical examination findings or laboratory investigations on the patient. All authors were substantially involved in drafting and editing the work, including substantial contributions in their respective areas of expertise and in review of the contributions of the other authors. All authors give their final approval of the version to be published and agree to be accountable for all aspects of this work.

The rest is here:
Central nervous system graft-versus-host disease in a 68-year-old man presenting with myoclonus - CMAJ

Sep 21, 2019 10:17 AM EDT

In the body's cells, some proteins are of vital importance as to which genes are active or turned off. Now, researchers from the University of Copenhagen and the Memorial Sloan Kettering Cancer Center have discovered which proteins are necessary in order to maintain the proper genetic regulation.

All of the more than 200 different cell types in our body contain the same DNA. Which of those genes that are expressed determine each cell type. Therefore, it is essential that the activity of the genes is controlled with great precision.

Thus, a stem cell may develop into anything from skin to a bone cell, depending on which parts of the genome that are expressed.

The researchers in Professor Kristian Helin's research group have for several years worked to understand the mechanisms that control whether a gene is active or inactive. This research is crucial to the understanding of how cells become specialized and maintain their identity, the normal embryonic development, and how various diseases may develop.

In a new study, researchers working at the Biotech Research & Innovation Center (BRIC) and the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen as well as the Memorial Sloan Kettering Cancer Center in New York have achieved crucial new results.

The results were recently published in the scientific journal Molecular Cell and provide insight into the ways in which epigenetic mechanisms control the activity of genes.

'In addition, the results may have an impact on the future treatment of certain cancers related to the studied protein complex, including lymphoma, leukemia and a special type of brain cancer that is often seen in children', says Kristian Helin, Professor at BRIC and Director of Research at the Memorial Sloan Kettering Cancer Center.

Turning On and Off

One of the key protein complexes that regulate whether genes are turned on or off is called PRC2. To ensure that the complex binds to the right places in the genome, a number of other proteins are associated with PRC2.

In the recently published article, the research group has studied the importance of six different proteins associated with PRC2, and the group has shown that all six proteins help direct PRC2 to the right places in the genome.

In 15 different combinations, the researchers removed the associated proteins from embryonic stem cells one by one. In this way, the researchers were able to study the contribution of each protein to the activity and binding of the PRC2 complex to specific areas. It was found that the ability to find the way to the right places in the genome remained intact until all six associated proteins were removed from the stem cells.

That finding surprised the researchers, says the study's lead author, Postdoc Jonas Hjfeldt:

'We assumed that each of the associated proteins was responsible for its own area to where the PRC2 complex should be guided. Instead, we saw that they all contributed to the places where the complex binds. As long as just one of the associated proteins were left, the ability remained intact', he says.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

See the article here:
New Insight as to How Cells Maintain Their Identity - Nature World News

Youll be glowing.

Skincare brand Andalou has introduced a new product line to its naturally-derived offering, citing hemp as a total skin saver.

The brand formulates its innovative products around fruit stem cell science, which utilises antioxidants that occur in apples, grapes and other natural ingredients.

For the new CannaCell range, stem cells are extracted from the stalk of hemp plants and included in each product along with organic hemp seed oil.

While the vitamin and protein-rich oil helps soothe distressed skin and boost water retention, the stem cells work to prevent oxidative damage, and counteract sun exposure and pollution.

Leading the pack for the new line is Andalous CannaCell Glow Mask. The exfoliating, botanical enzyme-based mask has a jelly-like consistency and warms the skin while it works its magic.

Then, after a relaxing 10-20 minutes, youll find your skin hydrated, soothed and glowing.

The CannaCell range is available online now.

@andalounaturals_au

See original here:
You can now use plant stem cells to rejuvenate your skin - Fashion Journal

The news that Formula One legend Michael Schumacher was moved to a hospital in Paris last week for pioneering stem cell therapy has provoked a fever of hope and speculation among fans that his condition could be improved.

After suffering devastating head injuries in a ski accident almost six years ago, Schumacher was placed in a coma for six months and has been receiving treatment at his home in Switzerland. He has not been seen in public since the accident.

His privacy is closely guarded and, while it is understood he cannot walk or stand, and, according to former Ferrari manager, Jean Todt, he may still have trouble communicating, nothing has been confirmed officially.

No wonder then that fans have been so excited to hear Schumacher is now under the care of world-renowned cardiac surgeon Philippe Menasch, described as a "pioneer in cell surgery" at the Georges-Pompidou hospital in Paris.

READ MORE:* Schumacher 'conscious' after treatment*Corinna Schumacher provides rare update*Schumacher 'struggles' to communicate*Mick Schumacher trying to emulate his dad

Stem cells are cells that can differentiate or change into other types of cell, opening the possibility of replacing damaged cells with healthy ones. Scientists have been looking into their use since the Sixties, most successfully so far in cases of cancers of the blood or bone marrow. More than 26,000 patients are treated with blood stem cells in Europe each year.

And since the Eighties, skin stem cells have been used to grow skin grafts for patients with life-threatening burns; most recently, a new stem cell-based treatment to repair damage to the cornea (the surface of the eye) after an injury like a chemical burn, has received conditional approval in Europe.

But their flexibility offers hope for lots of illnesses and conditions including heart disease, MS and macular degeneration and clinical trials are progressing in all these areas. Chronic spinal cord injury is being researched with some promise, thanks to the Christopher & Dana Reeve Foundation, set up after actor Christopher Reeve was paralysed in a riding accident.

Crucially, for cases such as Schumacher, stem cells are also being explored for neurodegenerative diseases like Parkinson's and Alzheimer's and traumatic brain injuries like the one he suffered in a skiing accident in December 2013.

Head injuries are difficult to treat as brain damage cannot be undone and each case is different. Asked for comment by The Daily Telegraph, the hospital responded that they could neither confirm nor deny the presence of Schumacher.

However, if he is under the care of Menasch, it is likely he will have had stem cells delivered by an IV to the area of the body where it is felt they could work best - whether that is his head or heart.

CHRISTOPHE ENA/AP

Paris' Georges-Pompidou Hospital, where Michael Schumacher is reportedly a patient.

In a recent interview online, Menasch explained that stem cell treatment for cardiac conditions - his particular area of expertise - is in its infancy. "Nobody really knows how stem cells are working," he said. "They do not permanently transplant into the myocardium [the muscular tissue of the heart] - after a couple of days or weeks, they just disappear.

"But you still may have a functional benefit as during their transient stay in the heart," he explains in the Future Tech podcast, "as the cells release molecules into the tissue. The hypothesis is that the repair comes from the heart itself, stimulated by these molecules."

Should the stem cells have been intended for Schumacher's brain injury, research suggests that the treatment has potential. A University of Plymouth study published in the journal Cell Reports in June found that neural stem cells could be used to "wake up" and produce new neurons (nerve cells) and surrounding glial cells in the brain.

The research is in its infancy, says lead author Dr Claudia Barros, from the Institute of Translational and Stratified Medicine at the University of Plymouth, who acknowledges there is still a long way to go until such findings can be translated into human treatments.

"We are working to expand our findings, to bring us closer to the day when human neural stem cells can be controlled and efficiently used to facilitate brain damage repair, or even prevent brain cancer growth that is fuelled by stem-like cells," she says.

A Chinese study published last month in the journal Frontiers in Cellular Neuroscience examined the current state of progress into the effects of stem cell therapy on traumatic brain injury. But the researchers from Zhejiang University, Hangzhou warned much more work was needed: "Although a large number of basic studies have confirmed that stem cells have good effect in the craniocerebral injury," they said, "the safety of stem cells, the route of injection, the time of injection and the specific mechanism are all factors that affect the clinical application of stem cells, and are the important research point in the future study."

PREMA TEAM

Mick Schumacher doesn't mind the comparisons with his seven-time F1 champion father Michael.

In the UK, some applications of stem cell medicine are already available privately, although tightly controlled by the Human Tissue Authority and not in the brain.

Simon Checkley, CEO at the Regenerative Clinic in Brighton, explains: "It is possible to get stem cells from sources outside your body, like the umbilical cord or Wharton's jelly [the vitreous humour in the eyeball], but in the UK we can only take stem cells from our own bodies.

"It is possible to get them donated, but it is safer to use your own."

In some countries, stem cells can then be manipulated in a laboratory but that is illegal in the UK, says Checkley. "There is a concern with cultured stem cells which have been bred in a Petri dish that they may keep proliferating after you transplant them into a body. That, having triggered their growth, you can't stop it and no one knows what might happen."

At the Regenerative Clinic, stem cells are taken from adipose fat, where they are plentiful, and then injected back into the area to be treated - mostly arthritic joints.

"We are seeing fantastic results," Checkley says, "with reduced pain and improved mobility for 80 per cent of patients." He is considering a clinical trial which could see the treatment pass through the National Institute for Health and Care Excellence (NICE) and become available on the NHS.

The therapy is still only four years old, he emphasises. "We have treated 1000 patients so far and around the world, it's about 40,000. We need longer-term studies."

LUCA BRUNO/AP

Michael Schumacher has not been seen in public since suffering a serious brain injury in a skiing accident nearly six years ago.

This type of stem cell treatment is also offered in the UK for post-menopause vaginal atrophy and stress incontinence, Checkley says, plus the genital skin condition lichen sclerosis. In all these cases, he says, the mechanism is the same: the stem cells are not replicating dead or dying cells but acting as signalling devices, alerting the body that this is an area where healing is needed.

For stem cells to work in more complex conditions, they would need to be manipulated, Checkley says. In cases of brain injury or disease, that would mean altering stem cells so that they could be targeted more precisely. But he believes the role would be similar: "The idea is they would go to the area of greatest damage and signal the body to regrow tissue there."

Cost would be a huge factor, he points out. A treatment for arthritis costs about 6000 (NZ$11,700) at the Regenerative Clinic but an IV-led treatment for brain injury with manipulated stem cells could cost up to 50,000 (NZ$98,000). But then what price recovery from a traumatic brain injury? Full recovery thanks to stem cells would be a prize beyond value.

See original here:
Reported stem cell treatment could give hope to Michael Schumacher - Stuff.co.nz

The legal and regulatory tools designed to protect the public from the marketing of unproven stem cell therapies will remain ineffective without bureaucratic will and grassroots efforts, according to a University of Alberta health law expert.

There's this perception that stem cells are revolutionizing science and they have transformed medicine already, but that's just not the case, said Timothy Caulfield.

You see the word stem cells being used to sell everything from skin cream to sports recovery tools to supplements, it's absolutely everywhere.

Caulfield, who refers to the marketing of spurious stem cell treatments as scienceploitation, explained there are actually only a handful of such therapies that have been approved for use in a clinical setting.

The most well known is probably the use of stem cells in bone marrow transplants and certain kinds of leukemiabut these therapies have been around for decades, he said, adding other stem cell therapies have shown some effectiveness in the treatment of bad burns and blindness.

But that's it.

In a paper outlining a strategy to combat the spread of misrepresentation within this field, Caulfield and Health Law Institute research associate Blake Murdoch argued the first step is to leverage the powers wielded by the provincial colleges of physicians and surgeons.

We need a more robust response from them because they have the power to stop their members from marketing treatments inappropriately and from offering services that are unproven, said Caulfield.

We haven't seen that, and it really is their role to protect the public.

He added organizations aimed at stopping the spread of misinformation and inaccurate marketinglike Ad Standards, Canadas advertising industry's non-profit self-regulating body, or Competition Bureau Canada, the federal advertising regulatorcan also be more involved.

While the Competition Bureau can only prohibit clinics from using misleading advertising and

not the provision of unproven interventions, this would help to stop the spread of misinformation, which may curtail public interest, said Caulfield.

He added political pressure on federal and provincial lawmakers could encourage change and allow a more comprehensive response, but noted that targeting the marketing of these treatments might be the more politically palatable course of action.

I think a really good logical first step is if you're going to market this stuff, if you're going to offer these services, the information you're using to market the services has to be accurate.

Even as the paper was being published, Caulfield said Health Canada weighed in by stating stem cell therapies need its approval.

Basically, if youre an MD, and you're providing stem cell therapy, you need to get it approved, said Caulfield. In the paper, we said Health Canada has got to get more aggressive, and thankfully, we're starting to see some action in that space.

He said ultimately, however, responses from Canadas regulatory bodies are often triggered by complaints from the public.

I've actually spoken to regulators, and theyre not hearing complaints about people being injured by stem cell treatment, said Caulfield. Of course, just because something is safe, doesn't mean it's a good idea.

Not only have some of these treatments shown to have caused real harm while offering little more than hope, Caulfield said there is a financial exploitation element, all of which can only leave a black mark on the science.

The spread of clinics marketing these interventions may, over the long term, damage public trust in legitimate regenerative technologies, thus adversely impacting their future development, he said. It confuses what is an incredibly promising field.

The most perplexing element of the proliferation of these treatments is the involvement of medical professionals who should know better, Caulfield said.

The team went into the analysis with the hypothesis that alternative practitioners were the ones providing and marketing stem cell therapies. This was true, but Caulfield said they were surprised to find that an MD was often involved.

I've been in the room with these health providers, and you get the sense that many of them believe it works.

More:
Regulatory heft needed to curb false promises on stem cells, says health law expert - Folio - University of Alberta

Scientists have developed a baseball cap that zaps your scalp and could reverse male balding.

Experts first created a wireless patch that can stimulate the scalp with electric pulses to encourage hair growth.

The 0.4-inch-thick plastic patch contains layers of differently charged materials that produce electricity when they come into contact and separate again.

Its a phenomenon known as the triboelectric effect and can result in faster hair re-growth than being hooked up to a machine for several hours a day. The team, from the University of Wisconsin-Madison, tested it out on the backs of shaved lab rats and found that when they moved it caused the flexible patch to bend and stretch.

They found that this movement activated the triboelectric effect and noted faster growth than in rats who had been given minoxidil lotion a common hair loss treatment.

Next the team, led by Xudong Wang, tested the patch on mice that were hairless because of a genetic deficiency.

They found that after nine days, 2-mm-long fur had grown on their skin under the patch compared with 0.8-inch-long hair that had grown on skin treated with minoxidil.

The density of the hair was also three times greater for the patch-treated areas.

Wang also tested the patch on his dad, who has been going bald for the past few years.

It helped him to grow a lot of new hairs after one month, he told New Scientist.

His team has now designed a baseball cap that encases the whole scalp in triboelectric materials.

Wang is seeking approval to test it in men in a clinical trial.

He says it shouldnt be uncomfortable to wear because it produces very gentle electric pulses.

However, the hat will only work in men who are currently losing their hair or have recently become bald, because the skin loses its ability to generate new hair follicles after many years of baldness, he added.

Its also unlikely to work as well when men sleep because they dont produce as many movements to power the device.

Small head movements during normal daily activity should be enough to power the device, he added.

Previously, we reported on a breakthrough treatment from a team of scientists who say they have used stem cells to develop a way of making unlimited hair.

In groundbreaking trials, human cells were grafted on to mice cells and attached to tiny scaffolds to help them grow straight.

They were then placed under the skin and emerged through it.

The team is now working toward tests on humans.

Around four in 10 Brit fellas suffer some form of baldness.

Read more here:
Cap that zaps your scalp could reverse male balding - New York Post

While manycelebrities swear that "tons of water and leafy greens" are the onlytwo factors behind an angelic red-carpet glow, Mandy Moore has alwaysbeen an open book with her fans, constantly documenting her friendship with herlongtime glam squad, the Streicher Sisters, and the work it takes to prep for abig event. Another piece of her glam squad she relies on, especially beforetomorrow's Emmy Awards? Her facialist.

In preparation fortomorrow's show, the This Is Us starwill be visiting her esthetician, Biba de Sousa, in Los Angeles for a specific"Red Carpet Skin Prep" treatment, complete with a very traditional,very interesting-looking facial that promises standout results. Below, the step-by-step from the skin expert herself.

You May Also Like:The 8 Beauty Products Mandy Moore Calls Her Favorites

Step one: For agentle, non-abrasive cleanse, de Sousa's soon-to-be-released micellar waterwill be used all over the skin, then she'll apply a "hydrating enzymaticmask to remove dead skin cells." Up next is lymphatic drainage of the faceand entire upper bodya must-try if you're looking to de-puff before a bigevent.

Now for the funstuff. Moore doesn't just get any old facialde Sousa incorporates a"DermaCulture system"with galvanic current, which she describes as one of the oldestaesthetic modalities (it got pushed aside by microcurrent machines). In fact,the machine is no longer manufactured"you have to wait until anesthetician retires in order to get their machine," she adds.

The time-testedtreatment consists of layers of gauze bandages soaked in a specificsolutionthink yucca root extract, magnesium sulfate, zinc sulfate and vitamin Capplied to the skin. Then, an old-timey galvanic mask is applied on top"to target tissue rejuvenation and firming via galvanic currents," deSousa explains. While definitely scary-looking (see below for proof from a brave beauty editor!), the results are said to be nothing short of incredible.

The finishing touch: a peptide-infused plant stem cell serum to keep skin looking dewybut we know what the real secret is.

Sign up to receive our newsletter

Excerpt from:
Mandy Moore Relies on a Galvanic Facial Before the Red Carpet - NewBeauty Magazine

HTF MI recently Announced Global Stem Cells study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Stem Cells. Global Stem Cells research allows you to get different methods for maximizing your profit. The research study provides estimates for Global Stem Cells Forecast till 2025*. Some of the Leading key Companys Covered for this Research are CCBC, Vcanbio, Boyalife & Beikebiotech.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market.

Click to get Global Stem Cells Market Research Sample PDF Copy Here @:https://www.htfmarketreport.com/sample-report/928542-global-stem-cells-market-3

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.The global Stem Cells market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.

Global Stem Cells Research for a Leading company is an intelligent process of gathering and analyzing the numerical data related to services and products. This Research Give idea to aims at your targeted customers understanding, needs and wants. Also, reveals how effectively a company can meet their requirements. The market research collects data about the customers, marketing strategy, competitors. The Stem Cells Manufacturing industry is becoming increasingly dynamic and innovative, with more number of private players entering the industry.

Important Features that are under offering & key highlights of the report:

1) Who are the Leading Key Company in Global Stem Cells market space?

Following are list of players that are currently profiled in the report CCBC, Vcanbio, Boyalife & Beikebiotech

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.2) What will the market size be in 2025 and what will the growth rate be?In 2019, the Global Stem Cells market size was xx million USD and it is expected to reach USD xx million by the end of 2025, with a CAGR of xx% during 2019-2025.

3) By What Applications & Types Does Market Study is Segmented:

The study is segmented by following Product Type: , Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell & Other

Major applications/end-users industry are: Diseases Therapy & Healthcare

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2018 currency rates.

To comprehend Global Stem Cells market dynamics in the world mainly, the worldwide Stem Cells market is analyzed across major regions. HTF MI also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/928542-global-stem-cells-market-3

Competitive Analysis:The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as CCBC, Vcanbio, Boyalife & Beikebiotech includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.Research Parameter/ Research Methodology

Primary Research:The primary sources involves the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Check for Discount, Offers ranging from 15% to 35% on Immediate Purchase on different Licenses @https://www.htfmarketreport.com/request-discount/928542-global-stem-cells-market-3

In this study, the years considered to estimate the market size of Global Stem Cells are as follows:History Year: 2013-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

Key Stakeholders in Global Stem Cells Market:Global Stem Cells ManufacturersGlobal Stem Cells Distributors/Traders/WholesalersGlobal Stem Cells Subcomponent ManufacturersIndustry AssociationDownstream Vendors

**Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Buy this research @https://www.htfmarketreport.com/buy-now?format=1&report=928542

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter|Google+

Link:
Stem Cells Market Will Generate New Growth Opportunities in the upcoming year - OnYourDesks

The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.

The global circulating tumor cells and cancer stem cells market is anticipated to grow at a rapid rate owing to development in biotechnology and biomedical engineering. According to WHO, Cancer is the leading cause of mortality and morbidity globally impacting about 14 million people annually, leading to rapid increase in research activities worldwide. Circulating tumor cells and cancer stem cells are under research for various types of cancer such as breast cancer, lung cancer, colorectal cancer, skin cancer. Government and various government bodies are taking interest and initiative to boost funds and activities which is one of the major factor driving the growth of the global circulating tumor cells and cancer stem cells market. Increase in demand of oncology screening, diagnosis and treatment monitoring the patients disease progression is one of the factor likely to propel the growth of the market through 2024. Furthermore, application of the circulating tumor cell for the drug discovery, use of cells in development of tumor specific biomarkers for targeted therapies are driving the growth of the global market. However, the ethical issues involved in research and regulation to perform human trials are some of the major factor that are retraining the growth of the global market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13306?source=atm

Based on technology type, the global circulating tumor cells and cancer stem cells market is divided into following Cell enrichment Detection CTC Analysis

Based on Application types, the global circulating tumor cells and cancer stem cells market is divided into following Biomarkers Tumorigenesis Stem cell research Others

The global circulating tumor cells and cancer stem cells market is segmented on the basis of technology type, application type and geographical region. On the basis of technology type the global market is divided into cell enrichment, Detection and CTC Analysis. Enrichment is further divided into positive selection, negative selection, Microchips and others. Detection is further divided into Immunocytochemicals technology, Molecular based technology, EPISPOT functional invitro assay. Cell Enrichment accounted for the largest market share globally owing to higher usage in oncology research and highly accurate technology. Microchip technology is expected to register high growth in the global market due to introduction of cluster chip technology which enables to capture the clusters of circulating tumor cells. On the basis of application type, the global market is divided into Biomarkers, tumorigenesis, stem cell research and others.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/13306?source=atm

Geographically the global circulating tumor cells and cancer stem cells market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is the dominating region in the global market attributing to the factors like developed economy, developed healthcare domain, strong funding for oncology research, rise in prevalence rate of cancer, favorable initiatives by government bodies. Asia Pacific region is expected to register high growth during the forecast period as a result of awareness, development of research and healthcare domains and prevalence of cancer.

Some of the major player operating in the global circulating tumor cells and cancer stem cells market are QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics, LLC, CellTraffix Inc., Silicon Biosystems, Advanced Cell Diagnostics, Inc. among others worldwide. To maintain a significant position in the global market key players are involved in collaboration with the cancer research universities and hospitals, for example in November 2015 Epic Sciences announced collaboration Abramson cancer Centre of University Pennsylvania. This collaboration is expected to explore the field of biomarkers which are identified by circulating tumor cells. The key participants are expanding the market by developing the facilities in different regions. For example, in September 2014 advanced cell diagnostic Inc. established a subsidiary in Europe to serve the European market.

The report covers exhaustive analysis on: Circulating Tumor Cells and Cancer Stem Cells Market Segments Circulating Tumor Cells and Cancer Stem Cells Market Dynamics Historical Actual Market Size, 2013 2015 Circulating Tumor Cells and Cancer Stem Cells Market Size & Forecast 2016 to 2024 Circulating Tumor Cells and Cancer Stem Cells Market Current Trends/Issues/Challenges Competition & Companies involved Circulating Tumor Cells and Cancer Stem Cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/13306?source=atm

The rest is here:
Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 - Commerce Gazette

Today in science fiction becoming science reality researchers grew a series of mini-brains in a laboratory. Yes, you read that correctly. Perhaps you might not be shocked at all. Researchers have already gone on to 3D print organs like skin,a functioning heart, and a functioning pair of lungs. However, todays event did not require the process of additive manufacturing, which begs the question What will we do with the brains we grow? So lets jump in a little further.

Now researchers did not only grow a brain in the laboratory, but the mini-brain was also able to generate human-like brain waves. Published in the August 29 issue of Cell Stem Cell, the aim of this project was to find new ways to study brain disorders.

However, when you think about it, the project does raise some very difficult questions about when consciousness begins and where this research is going, questions that are sure to keep your Ethics 101 class going for the semester.

Alysson Muotri, a neuroscientist at the University of California, San Diego, grew over 100 mini-brains in Petri dishes in his lab. For the uninitiated, these brains can also be described as organoids. Muotri plans to use his organoids to study neurological disorders, like autism or epilepsy. Now, these brains are not fully functioning conscious beings like us, though philosophers might argue otherwise.

Brain organoids have been already created but Muotris creation is special. As mentioned above, his brains are active, and have a functional human-like neural network, or a web of neurons that can transmit information across the brain.

RELATED:A COMPANY CREATES THE FIRST 3D PRINTED MINI HEART

Even though psychiatric conditions rarely make a physical appearance, you could even use these brains to study diseases like schizophrenia, bipolar disorder, or depression as these diseases affect how the neurons connect and send electrical impulses throughout the brain.

Now the brain organoids were about the size of a pea and were grown using human stem cells over a 10 month time period. The next step of Muotris brain experiment is using the mini-brains for autism research as well as launching a company to make the organoids for commercial use, such as testing new drugs.

This work really shows that organoid has complex patterns of neural activity for future studies. They allow us to study whether (the brain waves) are altered in different diseases. We normally did not have access to study, saidMuotri.

Read the rest here:
Researchers Grow Pea-Sized Brains in Laboratory That Produce Detectable Brain Waves - Interesting Engineering

Skin is the largest organ of the human body. It is composed of three layers: epidermis-the outermost layer; dermis-contains sweat glands, hair follicles and connective tissue and hypodermis-made up of fat and connective tissue. The main functions of the skin includes protection, sensation and regulation. The skin acts as a barrier and provides protection against harmful chemicals, radiation, microorganism and changing environmental conditions. It also helps regulate body temperature and maintain fluid balance. Skin is an extensive network of nerve cells and contains various receptors to detect changes in the environment such as touch, pain, heat and cold. Damage to skin due to burn or trauma can disrupt all the vital functions performed by the skin.

Currently, topical antibiotics, skin grafting, wound dressings and tissue-engineered substitutes are available in the market that are used to treat skin-related disorders. A skin graft can be done by natural substitute such as amniotic membrane, potato peel or artificial material that includes synthetic polymer sheet, polymer foam or spray. These substitute helps in the healing process. Skin regeneration refers to the regrowth of the damaged skin from the remaining tissue. Stem cell therapy has a vital application in skin regeneration.

Dermal regeneration matrix device provides an appropriate environment that is necessary for the proliferation and differentiation of skin cells. It helps in triggering the bodys own repair mechanism by cell signaling, that drive the matrix environment in wound healing process. Dermal regeneration matrix device is used to treat skin burns and is also finds application in reconstructive surgery for contractures (scars). The dermal regeneration matrix device is placed over the damaged skin which provides an environment for regeneration of new skin and tissue. The matrix is made of cow collagen, silicone and shark cartilage.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/12166?source=atm

In 1996, the U.S. Food and Drug Administration (FDA) first approved integra dermal regeneration matrix device for treatment of burn injuries. In 2002, dermal regeneration matrix device was approved for use in reconstructive surgery for burn scars. About 30 million people in the U.S. are suffering from diabetes, of which 15% experience a diabetic foot ulcer in their lifetime. In January 2016, FDA approved the use of dermal regeneration matrix for treatment of chronic diabetic foot ulcers (DFU). The usage of dermal regeneration matrix device is expected to expand the growth of dermal regeneration matrix device owing to increase usage in chronic foot ulcer.

Technological advancement and continued research in the development of artificial skin promises to bring more products to the marketplace. Increasing adoption of the device and long-term benefits associated with its application are some of the factors expected to fuel growth of the global dermal regeneration matrix device market over the forecast period. However, less awareness among the consumers and high cost of device are some of the key factors that could hamper growth of the market.

The global dermal regeneration matrix device is segmented on the basis of source, application, end user and geography. Segmentation by source Cow Collagen Silicone Shark Cartilage Segmentation by end user Hospitals Dermatology Centers Segmentation by application Burn Trauma Reconstructive Surgery Chronic Diabetic Foot Ulcers

On the basis of source, the global dermal regeneration matrix device market is segmented into cow collagen, silicone and shark cartilage. On the basis of end user, the global dermal regeneration matrix device market is segmented into hospitals and dermatology centers. The hospital segment is expected to contribute significantly to the total market in terms of market share. According to World Health Organization, over 265,000 deaths are caused due to burns each year. The majority of the burn cases occur in low and middle-income countries. Injuries such as traffic collisions, falls, burns, drowning, poisoning and others are expected to kills around five million people worldwide. Thus, the demand for dermal regeneration growth matrix is expected to be high in the low and middle-income countries over the forecast period.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/12166?source=atm

On the basis of region, the global dermal regeneration matrix device market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

Some of the major players in the global dermal regeneration matrix device market include Integra LifeSciences Corporation, Platelet BioGenesis, Avita Medical, Stratatech, Organogenesis Inc., Smith & Nephew, Inc., ACell Inc., Symatese and others.

The report covers exhaustive analysis on: Dermal Regeneration Matrix Market Segments Dermal Regeneration Matrix Market Dynamics Historical Actual Market Size, 20132015 Dermal Regeneration Matrix Market Size and Forecast, 20162024 Dermal Regeneration Matrix Market Current Trends/Issues/Challenges Competition and Companies Involved Dermal Regeneration Matrix Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting industry dynamics In-depth market segmentation Historical, current and projected industry size and recent industry trends Key competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/12166?source=atm

View original post here:
Dermal Regeneration Matrix Device Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2025 - The Market...

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/23101?source=atm

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography: Segmentation by Treatment Allogeneic Amniotic Fluid stem cell therapy Autologous Amniotic Fluid stem cell therapy Segmentation by Application Regenerative medicines Skin Orthopedics Oncology Fetal tissue reconstruction Kidney regeneration Regeneration of neural tissue Cardiac regeneration Lung epithelial regeneration Others Drug research and development Segmentation by End User Hospital Ambulatory Surgical Centers Specialty Clinics Academic and Research Institutes Segmentation by Geography North America Latin America Europe Asia-Pacific Excluding China China Middle East & Africa

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/23101?source=atm

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on: Amniotic Fluid Stem Cell Therapy Market Segments Amniotic Fluid Stem Cell Therapy Market Dynamics Historical Actual Market Size, 2012 2016 Amniotic Fluid Stem Cell Therapy Market Size & Forecast 2016 to 2024 Amniotic Fluid Stem Cell Therapy Market Current Trends/Issues/Challenges Competition & Companies involved Amniotic Fluid Stem Cell Therapy Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Excluding China China The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/23101?source=atm

Originally posted here:
Amniotic Fluid Stem Cell Therapy Market New Growth Opportunities By2018 2026 - Market Reporter

Cultured meat also called lab-grown, cell-based, and clean meat could be on dinner tables sooner than once thought. The futuristic cellular agriculture industry is only becoming busier and some say lab meat could be available as soon as 2021.

Lab-grown meat is produced by in vitro cultivation of animal cells. Cellular agriculturists collect a small sample of cells from an animal. These can come from swabbing skin tissue, a feather, etc. The cells must have a rapid rate of proliferation, like embryonic stem cells, adult stem cells, myosattelite cells, or myoblasts.

The cells are placed into a nutrient-rich solution, called a growth medium, in a controlled cultivator. This causes the stem cells to act as they would if they were still in the animals body to multiply, ideally quickly and into high densities.

The result is an edible product that looks, cooks, and tastes like animal meat because, biologically, it is animal meat. The major difference is that an animal does not need to be killed to make it.

Lab-grown meat is meat, meaning it is not vegan. However, the concept may create a loophole for some due to the fact that it can be made without the slaughter of animals.

Not all lab-grown meat production is free from animal use. Dutch scientist Mark Post, who presented the worlds first lab-grown burger at a press conference in 2013, grew cells in an animal-based broth to make his clean meat patty.

He said the most efficient method of cellular agriculture involves the slaughter of animals. Eventually my vision is that you have a limited herd of donor animals in the world that you keep in stock and that you get your cells from there, Post told The Telegraph.

Fetal bovine serum (FBS) poses an issue for vegans interested in lab-grown meat. FBS comes from the blood of a cow fetus and its the most widely used serum-supplement in the industry for eukaryotic cells.

However, some producers, like food tech company JUST, make a point of keeping the entire process cruelty-free. In a video, JUST shows how it developed its lab-grown chicken. For those very first cells, it was important to us how we got those cells, not just that we got the cells, JUST said. We came up with the idea to use one feather from the single best chicken that we could find.

The team waited for the chicken, whose name is Ian, to naturally drop a feather. The researchers then collected cells from this feather, enabling Ian to live on unharmed, but significantly important to the cause. The JUST team feasted on real chicken nuggets while Ian wandered around their feet, alive and well.

Ryan Bethencourt co-founder of the worlds leading life science accelerator, IndieBio believes lab-grown meat can bridge the gap between peoples hunger for meat and their desire to do less harm. The aim is to ensure that people keep eating what they love, but to produce it in a way so its not damaging the planet, Bethencourt, who is a vegan, said to the Guardian.

Conventional meat comes with its risks. In 2015, the World Health Organization (WHO) named red meat a Group 2 carcinogen, meaning it probably causes cancer in humans. WHO placed processed meat like bacon in the Group 1 category, meaning it is carcinogenic to humans. Asbestos and tobacco smoking are also in this category.

Post believes lab-grown meat could be safer for consumption than traditional meat. The creator of the first clean meat burger said to The Atlantic, We gain greater control over what the meat consists of, for example, its fat content.

And the reduction in the number of farmed animals reduces the chance of zoonosis, he added, referring to infectious diseases that can be passed from animals to humans.

JUST holds a similar view. It said in its video, One of the biggest points of comparison between what were doing and the old way of doing things is food safety.

JUSTs video displays a list of the risks associated with conventional meat, including salmonella, swine flu, giardia, fecal contamination, campylobacter, mad cow disease, foot-and-mouth disease, and avian chlamydiosis. It points out that clean meat carries none of these risks. And when you make that comparison, the difference is staggering, the company says.

Physician Neal Barnard, founding president of the Physicians Committee for Responsible Medicine (PCRM), believes lab-grown meat could be fortified to include extra nutrients like B12, in the same way vitamin D is added to orange juice.

The FDA and the USDA announced in March that they have established a framework to regulate clean meat. Its still in its preliminary stages but that hasnt curbed interest in the concept of clean meat. A study released by The Good Food Institute found that 66 percent of Americans are open to eating meat made in a lab.

Five food companies working within the cellular agriculture industry recently banded together to form the Alliance for Meat, Poultry & Seafood Innovation (AMPS Innovation).

AMPS Innovation aims to educate consumers and stakeholders about the industry and look at effective marketing for their products. The companies are also working with the government to establish a regulatory framework.

The founding members include Fork & Goode, JUST, and Memphis Meats, as well as cell-based seafood producers BlueNalu and Finless Foods. Representatives from these companies have met once a week for the last year to discuss obstacles faced by the industry.

The alliance has formed at an apt time, suggests Lou Cooperhouse, CEO of BlueNalu. This industry is maturing and is a lot more near-term than was thought of in the last year or in the past, Cooperhouse said in a statement. This is not something that is 10 years away. It is something that is short-term.

Lab-grown meat is not commercially available yet, but its launch may not be far off.

A recent report by global consultancy AT Kearney stated that by 2040, most of the meat people eat will not come from slaughtered animals. Sixty percent of meat will be either plant-based or cultivated in a lab.

The large-scale livestock industry is viewed by many as an unnecessary evil, the report said. With the advantages of novel vegan meat replacements and cultured meat over conventionally produced meat, it is only a matter of time before they capture a substantial market share.

It later added, Cultured meat will win in the long run.

Traditional animal agriculture leaves an undeniable mark on the planet. Its resource-intensive and generates huge amounts of greenhouse gas emissions. The United Nations Environment Programme (UNEP) named meat the worlds most urgent problem, saying that using animals for food has brought us to the verge of catastrophe.

The greenhouse gas footprint of animal agriculture rivals that that of everycar, truck, bus, ship, airplane, and rocket shipcombined, UNEP said. There is no pathway to achieve the Paris climate objectives without a massive decrease in the scale of animal agriculture.

Swapping to lab-grown meat could alleviate some of this damage. The CEO of Memphis Meats Uma Valeti said to the Guardian, If the US switched to Memphis Meats beef, we would expect the greenhouse gas reduction to be like taking almost 23m cars off the road. One burger could save the amount of water used in 51 showers.

Tim Noakesmith the founder of VOW, which is working on lab-grown kangaroo meat believes cell-based meat could help feed the worlds growing population. Its pretty insane, but its super important, its incredibly important, he said to Nine News. Weve reached the scale capacity in terms of creating food using traditional animal agriculture and we see that meat consumption is going to be rising and rising over coming decades.

VOW says its lab-grown kangaroo meat could be in supermarkets by the end of 2022. Its also speaking with top-tier chefs in Australia to explore the incorporation of its product into meals.

Other lab meat producers have similar goals. Japanese startup IntegriCulture Inc. wants to see its slaughter-free foie gras served in restaurants by 2021 and on the consumer market by 2023.

CEO of JUST Josh Tetrick took to Twitter in October to tease the launch of JUSTs lab-grown chicken nuggets. The company hasnt announced concrete plans, but Tetrick took the cruelty-free nuggets to the UK in January so that English TV presenter Helen Skelton-Myler could taste-test them. Tetrick explained, It is a nugget that didnt require killing a chicken and thats the way all meat should be. We dont need to choose between veggie burgers and a real burger.

Even the meat industry is clocking on to the notion. Agricultural giant Cargill invested in lab-grown meat company Aleph Farms earlier this year. Cargill, which controls more than 20 percent of Americas domestic meat market, has also invested in Memphis Meats.

Major meat producer Tyson Foods has also invested in Memphis Meats. Its also an investor in Israeli clean meat startup Future Meat Technologies. Justin Whitmore, Executive Vice President, Corporate Strategy and Chief Sustainability Officer of Tyson Foods, spoke about the move at a panel event in 2018. We dont want to be disrupted, he said.We want to be part of the disruption.

Summary

Article Name

What Is Lab Meat and Is It Vegan?

Description

Cultured meat -- also called lab-grown, cell-based, and clean meat -- could be available as soon as 2021. But what is lab meat? And is lab meat vegan?

Author

Jemima Webber

Publisher Name

LIVEKINDLY

Publisher Logo

More here:
What Is Lab Meat and Is It Vegan? - LIVEKINDLY

Blood vessels are the lifeline of any organ.

The dense web of channels, spread across tissues like a spider web, allow oxygen and nutrients to reach the deepest cores of our hearts, brains, and lungs. Without a viable blood supply, tissues rot from the inside. For any attempt at 3D printing viable organs, scientists have to tackle the problem of embedding millions of delicate blood vessels throughout their creation.

Its a hideously hard problem. Although blood vessels generally resemble tree-like branches, their distribution, quantity, size, and specific structure vastly differs between people. So far, the easiest approach is to wash out cells from donated organs and repopulate the structure with recipient cellsa method that lowers immunorejection after transplant. Unfortunately, this approach still requires donor organs, and with 20 people in the US dying every day waiting for an organ transplant, its not a great solution.

This week, a team from Harvard University took a stab at the impossible. Rather than printing an entire organ, they took a Lego-block-like approach, making organ building blocks (OBBs) with remarkably high density of patient cells, and assembled the blocks into a living environment. From there, they injected a sacrificial ink into the proto-tissue. Similar to pottery clay, the ink hardens upon curingleaving a dense, interconnected 3D network of channels for blood to run through.

As a proof of concept, the team printed heart tissue using the strategy. Once the block fused, the lab-made chunk of heart could beat in synchrony and remained healthy for at least a week.

The technology, SWIFT (an eyebrow-raising backcronym of sacrificial writing into functional tissue), is a creative push into a new generation of 3D biofabrication. Although OBBs have been around, the team explained, little attention was previously paid to putting the Lego pieces together with blood vessels.

This is an entirely new paradigm for tissue fabrication, said study author Dr. Mark Skylar-Scott. The focus is on vessels, which will support 3D printed living tissue that may eventually be used to repair damaged parts of a natural body, or even replace entire human organs with lab-grown versions, he added.

[Its] beautiful work, commented tissue engineer Dr. Jordan Miller at Rice University, who was not involved in the study.

SWIFT straddles two wildly diverse fields across centuries: organoids and 15th-century lost-wax sculpturing.

Youve heard of organoids. Often dubbed mini-organs, these lentil-sized blobs of tissue remarkably mimic particular aspects of entire organsbrain organoids, for example, show the characteristic nerve cell types of firings of a preemie baby. The cellular inhabitants that make up organoids are what especially caught the teams attention: most are grown from induced pluripotent stem cells (iPSCs), which are often skin cells de-aged in a way that they can develop into almost any cell type with a little chemical prodding.

Because organoids are built from a patients own cells, theyre completely compatible with the host for an immune standpoint. That particular strength caught the teams attention: organoids, they reasoned, make the ideal OBBor Lego piecesto biomanufacture patient- and organ-specific tissues with all the desired properties.

For example, the team explained, organoids are packed with a high density of cells, which is usually hard to achieve with traditional 3D tissue printing. Under the right conditions, they also develop similarly to real organs in terms of cellular composition and microarchitecture to support functionfor about a year. Without a blood vessel network, all organoids die.

Heres where lost-wax technique comes in.

First, a very brief explainer. Throughout the Renaissance, the majority of Italian sculptors used the technique to fabricate bronze statues. In the simplest method, a statuette is first modeled in beeswax and covered in potters clay. Once dried, the assembly is heatedthe clay is fired into ceramics, and the wax melts and flows away (hence, lost). Once cooled, the entire project is now a hollow ceramic mold, through which the artist can pour in molten metal.

Now, replace beeswax with sacrificial bio-ink, and thats pretty much how SWIFT carves out its intricate tunnels of blood vessels.

The entire fabrication process is two main steps. The team first grew hundreds of thousands of proto-organoids inside culture dishes. These tiny blobs are so small they dont yet need to be churned inside a bioreactor, but theyre mightily packed with roughly 200 million cells every milliliterabout the bottom bit of a teaspoon. These make up the techniques building blocks, or OBBs.

Next, roughly 400,000 OBBs are mixed with a dense, gel-like liquid with the consistency of mayonnaise at a low temperature. The liquid is filled with collagen, a protein that keeps our skin elastic, and other synthetic versions. The OBBs are now somewhat suspended inside the gel-like matrix, which is ideally suited for creating vascular channels, the team said. Altogether, the organoids and gel are compacted into a density similar to human tissue, making up the raw material for further sculpting.

Now the fun second step. Using a 3D printer, the team moved a tiny nozzle containing both harmless red ink and gelatin into the mixture, depositing both in a pre-programmed manner. In this way, the team was able to draw intricate branch-like patterns into the organoid-gel mixture. Similar to squeezing frosting out of a bag, the team was able to adjust the diameter of the gelatin ink by nearly two-fold, mimicking the usual structure of blood vesselsthick main channels that increasingly become tinier.

Once the network was fully printed, they then gently heated the mixture to body temperature. The matrix stiffens, and the gelatin inkacting like Jello left under the sun for too longmelts and is washed away. What remains is a network of OBBS, or organoids, linked with a vascular structure that can now be filled with blood.

As a proof of concept, the team went straight for the heartcardiac tissue, that is. They repeated the steps using heart-derived cells, and kept the resulting chunk of heart, a little bigger than half an inch inside a chamber, filled with a nutritious, oxygen-rich bath.

Within a week, individual organoids embedded inside the gel fused together into a collective: the tissue was able to contract almost 50 percent better than immediately after printing, and the beating rhythm synchronized, suggesting that the lab-grown tissue had further matured.

The tissue even reacted similarly to a normal heart. When the team infused a drug that increases heart rate into those printed vessels, the tissue doubled in its heartbeat. Similarly, drugs that normally decrease heart muscle contraction also worked on the mini-heart. As a final proof of concept demo, the team printed a chunk of heart tissue with a branch of the coronary arterya main blood vessel branch that normally wraps the heart.

The new study is hardly the first try at printing organs with blood vessels. Miller, for example, biomanufactured a hydrogel that mimicked a lung air sac earlier this May. Layer by layer, the precise anatomy of the lung-mimicking structure is constructed with liquid hydrogel, and solidified using light.

The new study stands out in its sheer creativity. By combining organoids with an ancient sculpture technique, the team was able to pack far more cells into the resulting structure, while tapping into the natural mini-organization that stems from organoids. The results arent just promising for printing larger, more intricate human organs with a blood supplythey could also help inform organoid research, which has struggled to keep the pseudo-organs alive.

The team is planning to transplant their SWIFT tissue into animals to further examine their function and health. But to the team, the main goal is to finally bring 3D-printed organs to people desperately on the transplant waiting list.

Our method opens new avenues for creating personalized organ-specific tissues with embedded vascular channels for therapeutic applications, they said.

Image Credit: Wyss Institute at Harvard University / CC BY-NC-ND 4.0

Read more from the original source:
How a Centuries-Old Sculpting Method Is Helping 3D Print Organs With Blood Vessels - Singularity Hub

Dr. Freda Miller, a senior scientist at the Hospital for Sick Children, has discovered that stem cells found in adult skin can produce nervous system Schwann cells.Fred Thornhill / Toronto Sun

A new elementary school in the citys southwest is being named after a scientist who is an alumna of the Calgary public school system.

The school that is under construction in the community of Evergreen is called Dr. Freda Miller School. The Board of Trustees of the Calgary Board of Education approved the name for the school, which is expected to open in September 2020.

Miller is a cell and molecular developmental neurobiologist at Torontos Hospital for Sick Children and a professor at the University of Toronto. She is also a fellow of theRoyal Society of Canada and the American Association for the Advancement of Science.

Miller has made seminal scientific discoveries over the course of her career, the Calgary Board of Education said in a news release Monday.

Her discovery of stem cells in the second layer of the skin has provided the conceptual basis for using skin as a major source for genesis of human stem cells. The stem cells she discovered are critical for the repair of injured skin, the release stated.

At the same time, Dr. Miller discovered new mechanisms determining whether nerve cells live or die, findings that initiated new fields of research and that have major implications for our understanding of neurodegenerative disorders.

Miller attended schools in Montgomery and Bowness and was part of the gifted program at Queen Elizabeth High School in her junior high years. She has a PhD in medical sciences from the University of Calgary.

The school board said Miller maintains strong ties to Calgary and lives part time in Canmore.

When Dr. Freda Miller School opens, it will serve students from kindergarten to Grade 4.

The rest is here:
New elementary school in Calgary named after scientist - Calgary Herald

Currently, there is no licensed treatment to slow or stop the progression of Parkinsons disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how their work could potentially slow disease progression.

Presenting as the second most common neurodegenerative condition after Alzheimers, Parkinsons disease affects 148,000 people in the UK alone. Most people present to their doctor with movement symptoms, such as a tremor, which is a classical symptom and what people often associate with Parkinsons, explains Dr Heather Mortiboys, from the University of Sheffields Institute for Translational Neuroscience (SITraN) and the Universitys new Neuroscience Institute. However, there are other symptoms that occur prior to the movement symptoms, such as loss of sense of smell, autonomic disturbances such as constipation and disordered sleep, particularly in REM sleep.

Most patients with Parkinsons are termed sporadic or idiopathic; meaning the cause of the disease is unknown. Only about 10 percent of patients develop Parkinsons through a known gene mutation, although some genetic association studies have identified several genes that might increase a persons risk of developing Parkinsons, according to Dr Mortiboys, who adds that this does not mean that the person will develop the disease.

Dr Mortiboys has been working in Parkinsons research for over 18 years and currently holds several senior positions, including Senior Research Fellow for Parkinsons UK. When asked about the aetiology of the disease, she explains: We know the type of brain cells that are lost in Parkinsons. They are in a specific brain region the midbrain and they contain the neurotransmitter dopamine. However, we dont know why these cells fail to function properly.

The team used a reprogramming technique utilising the patients skin cells to generate induced neuronal progenitor cells

Dr Mortiboys main research focus of late has been understanding what causes these dopaminergic cells to die in Parkinsons patients. If we can identify what is happening at the cellular level, then we can try to target them with drug therapy to stop them dying, or at least slow it down, she explains. Her team has focused their research on the cells powerhouse the mitochondria. Dopaminergic brain cells are heavily reliant upon their mitochondria. We know that in people with Parkinsons, the mitochondria dont function properly, but we dont really understand the reason why. We also dont know whether we can increase that function and if so, whether that will stop or slow the brain cells from dying.

To study the function of the mitochondria in patients with Parkinsons, the team took skin biopsies from the forearms of patients and cultured the cells in the laboratory. We took a large number of skin cells from a variety of different people with Parkinsons; some with a genetic type that causes early-onset Parkinsons, some with a genetic type that causes later-onset Parkinsons and then the largest group of patients was those with an unknown cause, explains Dr Mortiboys. Once the skin cells had been obtained, the researchers were able to investigate how well the mitochondria, and the associated pathways, functioned. As expected, we found that in all the patients, the mitochondria were not functioning properly in their skin cells. We also noticed that there were problems with the cells recycling pathways.

The next stage of their project was to identify a compound that would have a beneficial effect on boosting mitochondrial and lysosomal function. We started off with all of the drugs that are currently in clinical use, which was around 5,000, says Dr Mortiboys, noting that when developing a drug for neurodegenerative conditions, it needs to pass through the blood-brain barrier. Instead of screening all 5,000 drugs in the laboratory, we performed in silico computer screening to rank the compounds in their ability to pass through the blood-brain barrier.

Once the initial computer-based screening had been performed, the team ran a secondary screen to rank the compounds on their clinical characteristics. We looked at their known side effects, metabolism and dose range, says Dr Mortiboys. We ended up with a rank list of all the clinically in-use compounds and then screened the top ranked of these compounds in the patients cells for their beneficial effect on the mitochondria in the skin cell.

Since their initial work focused on patients skin cells, the team needed to validate their findings in dopaminergic brain cells, which are lost in Parkinsons. This can be particularly challenging because we cant easily take a brain biopsy from a patient, says Dr Mortiboys. The team therefore used a reprogramming technique utilising the patients skin cells to generate induced neuronal progenitor cells. We used a slightly modified protocol, which doesnt take the cells all the way back to being stem cells, explains Dr Mortiboys. Our method takes them to an intermediate, which can only become brain cell types. Crucially for us, it doesnt take them back to the embryonic state. The reason for this is that age is one of the biggest risk factors for Parkinsons and many other neurodegenerative conditions. We didnt want to wipe all the age-associated changes in the cell; so, with this reprogramming technique, we retained the changes that had happened throughout the cells lifetime while still producing a high percentage of dopaminergic cells.

Once these cells had been cultured, the team studied their mitochondrial function and observed that they were far more defective in the patients brain cells than in their skin cells. This showed us that it did matter which cells we were looking at it really was a problem with the mitochondria in the dopaminergic brain cells, explained Dr Mortiboys.

Building on their previous work, the team then looked at the beneficial effects of the previously identified compounds on the dopaminergic brain cells. We had identified several compounds that boosted mitochondrial function in the skin cells and we wanted to see their effects on the brain cells. For example, would they stop them dying off? Are they healthier when they have been treated with the compound? Do their neuronal features change?

Dr Mortiboys explains that they were able to identify compounds that had a beneficial effect, and this will be the focus of their research over the next year. With funding through the Virtual Biotech Programme the drug development arm of charity Parkinsons UK our aim is to take several of these lead compounds and chemically modify them. Well then test these chemicallymodified compounds in the dopaminergic patientderived system.

The aim is for the team to identify a lead molecule that retains mitochondrial function and can be progressed through the drug discovery pipeline.

As with all drug discovery research, there are several challenges the team must address. I think, going forward, the challenge for this project will be to fine tune the chemical lead compounds to dial up the beneficial effects and dial out the less desirable effects. Then, of course, there is the challenge of being able to test something in the laboratory and have confidence that it will translate into a beneficial effect in the clinic, says Dr Mortiboys.

Commenting on Dr Mortiboys research, Richard Morphy, Drug Discovery Manager at Parkinsons UK, said: This is an exciting new approach that could rescue defective mitochondria inside neurons to prevent dysfunction and degeneration of dopamineproducing brain cells. We hope the project will identify a superior group of molecules that could one day deliver a life-changing drug for people living with the condition.

The main symptoms of Parkinsons disease are:

A person with Parkinsons disease can also experience a wide range of other physical and psychological symptoms. These include: depression and anxiety, balance problems, loss of sense of smell (anosmia), problems sleeping (insomnia), memory problems.

Parkinsons disease is caused by a loss of nerve cells in part of the brain called the substantia nigra, which leads to a reduction of dopamine in the brain. Dopamine plays a vital role in regulating the movement of the body. The exact cause of the loss of nerve cells is unclear. Most researchers think that a combination of genetic and environmental factors is responsible.

Parkinsons disease affects around one in 500 people. Most people with Parkinsons start to develop symptoms when theyre over 50, although around one in 20 people with the condition first present with symptoms when theyre under 40. Men are slightly more likely to get Parkinsons disease than women.

Dr Heather Mortiboys gained her PhD from the International Max Planck PhD Program in Dresden, Germany in 2006. She then worked in the Neurology department at the University Hospital Dresden as a research associate on an EU funded project investigating coenzyme Q deficiency in patient tissue. Heather joined the Neuroscience department at the University of Sheffield to set up mitochondrial investigations in models of Parkinsons disease working as a postdoctoral research associate with Professor Oliver Bandmann. She recently became a Parkinsons UK Senior Research Fellow based within the Sheffield Institute for Translational Neuroscience (SITraN) to continue and expand this work setting up her own laboratory.

Original post:
Slowing progression in Parkinson's - avenues to explore - Drug Target Review

Since its launch in 2014, MONAT has taken the beauty world by storm, launching vegan, efficacious hair products and developing a massive global fanbase. Today, the brand is launching its highly anticipated skin-care collection, which has had 1 million VIP customers eagerly awaiting its arrival. Luckily for me, I was able to get my hands on the products early, and the complexion-perfecting formulas did not disappoint! Here's the scoop.

You May Also Like: Everything to Know About Stem Cells in Your Skin Care

Designed for busy people who need to glow on the go, the products are split into two collections: Be Gentle (Creamy Cleanser and Nourishing Moisturizer for dry and sensitive skin types)and Be Balanced (Foamy Cleanser and Lightweight Moisturizer for normal and combination skin types). Both duos are paired with the Skin Revitalizing Essence ($45) and Rewind Age Control Nectar ($120).There are also two special treatmentsa Berry Refined Scrub ($58), which is my personal favorite in the roundup that also doubles as a mask, and Eye Smooth ($75), which is literally one of the smoothest eye creams I've ever tried. A common thread throughout the line is the dreamy textures: think whipped butters and silky creams that make tedious skin-care routines feel luxurious.

And the creation of two collections adds that extra thoughtful touch we all look for these days. "How a product absorbs into the skin varies based upon an individualsskin type. Therefore, different skin types need different care," says Marlene Garcia, licensed medical aesthetician and the brand's senior manager of skin care education. "We formulated theMONAT Skincare line taking into consideration the science behind productabsorption into the skin because absorption plays an important role in how wellproducts can help optimize skin texture and elasticity while the minimizing theappearance of fine lines, wrinkles and age spots.

One big claim to fame for MONAT is that its formulas are "clean," and these new skin-care products are no exception. "MONAT literally means Modern Nature," says Jamie Ross, senior vice president of technical services and the brand's head of R&D."We use ingredients that arenaturally based, safe, pure and sustainablethe best nature has to offerbut we combine them into unique complexes that make thesenaturally based ingredients work in harmony with each other to pump up their existing properties. This is what takes MONATformulations to the next level. Weare also a global brand, and our skin care meets the rigorous cleaningredient standards of the EU. We have a go-to list of potentiallytoxic ingredients we will never use, and we're also cruelty-free and vegan. Aboveall, anything we bring to market must perform. Its one thing to be clean, but another to be clean andachieve the highest performance possible."

You May Also Like: How Easy Is It to Make the Switch to 'Cleaner' Living?

In regards to performance, one of MONAT's cult-favorite productsREJUVENIQE Oil Intensiveinspired its skin care. "We are known for our intensive hair oil, which has a base of Abyssinian oil and an invigorating, proprietary blend of 13 natural plant extracts and essential oils that are rich in omega fatty acids, antioxidants and nutrients," says Alan Meyers, the brand's chief science officer."The products primary role is a hair oil, but we had thousands of customers using it on their skin, too. When we officially launched into skin care, we took this same REJUVENIQE blend and carried it into our star products, including Rewind Age Control Nectar($120)."

Fans had been requesting skin care from the brand for years, but MONAT wanted the formulas to bring something new to the market rather than launching a line because everyone else was. That's one reason why brand presidentStuart MacMillan stressed the importance of doing clinical trials (a step many brands don't take due to the expense and time required). "We wanted to be naturally based AND efficacious," he says. "We wanted to be a disruptorwith key elements that made us unique. As such, the credibility of the productwas essential to us. Clinical trials reinforce the efficacy of our products andprovide credibility and confidence for our distributors." The results of such trials revealed 24 hours of skin hydration, and after14 days, 100 percent of users saw improvements to their skinsbalance, appearance and texture, and a more even skin tone.

You May Also Like: 22 Beauty Gifts Dermatologists Give Their Friends and Family

My personal favorite from the line is the Berry Refined Scrub, which smells like a Capri Sun, feels super gentle on my skin but is powerful enough to exfoliate away grime, and leaves my skin feeling SO soft. It also contains the brand's signatureREJUVENIQE blend, and it'sthe perfect skin prep for the Skin Revitalizing Essence, which has asubtle peach scent and watery texture that sinks right in.

You can buy the two collections (four products each) as sets for $278, or pick and choose, as each product is sold separately as well. Which one are you excited to try first?

Sign up to receive our newsletter

See original here:
MONAT Just Launched a Skin-Care Line and It's Everything You Hoped For - NewBeauty Magazine

Add this to your skin care kit

We're fortunate to be in an age where there's a solution for every skin problem that exists. Under the massive umbrella that is skin aging, there are many concerns and so many proposed solutions that it can befuddle the mind. We suggest you start off with an anti-aging serum. Serums contain higher proportion of active ingredients and penetrate deeper into the skin, which means better chances to improve texture, reduce lines and better elasticity. These 9 anti-aging serums are ideal for those with mature skin to target concerns of wrinkles, fine lines, age spots and sagging.

(Also Read:7 Sheet Masks For Every Anti-Aging Skin Concern)

The Plum Bright Years Age Specialist Cell Renewal Serum is powered by plant stem cell extracts that promote renewal, fight wrinkles and tighten skin in a 100% vegan and cruelty-free formula that comes in recyclable packaging.

The Biotique Bio Dandelion Visibly Ageless Serum has a preservative free blend of pure dandelion and nutmeg oil which are rich in vitamin E and minerals to brighten its tone, reduce spots as well as wrinkles.

The L'Oreal Paris Revitalift Laser X3 Renewing Anti-Aging Serum is inspired by dermatological procedures with concentrated actives like 3% Pro-Xylane and Adenosine. They work rapidly to provide triple action by smoothening skin, refining its texture and reducing wrinkles and lines.

The Lotus Professional Phyto-RX Intenstive Repair Anti-Aging Serum boosts production of collagen which lends skin with firmness and elasticity.

The Olay Regenerist Micro-Sculpting Serum is formulated with hyaluronic acid pentapeptides which penetrates the surface to regenerate cells from within which makes the face firmer and more lifted.

The Dot & Key Time Reverse Retinol Serum has peptide technology without parabens, sulphates or alcohol to minimize lines, fade spots and tighten skin.

The VLCC Vitalift Serum contains comfrey and soy to tighten skin and fade wrinkles in all skin types.

The La Roche-Posay Hyalu B5 Serum targets skin that is riddled with wrinkles, fine lines and sagginess. With hyaluronic acid and vitamin B5 as its heroes, it replenishes the skin's moisture barrier and activates renewal of cells.

The Sage Apothecary Face Serum has a host of ingredients like vitamin C and E, goji berry and hyaluronic acid which firms skin, reduces lines and shrinks pores.

Shop for similar serums here.

Add this to your skin care kit.

Here is the original post:
9 Anti-Aging Serums That Will Turn Back The Clock On Your Skin - NDTV

By TNH Staff September 20, 2019

(NASA, ESA, S. Beckwith (STScI), HUDF Team via AP)

A 31-year-old Greek woman who has racked up international acclaim as a renowned scientist isnt one, academics said, and the US space agency NASA said she never worked there as she claimed.

Eleni Antoniadou, 31, has won praise and awards around the world for her supposed work in a wide range of fields, including regenerative medicine, artificial organ bioengineering and space medicine at NASA.

The British newspaper The Telegraph said it was told by NASA she had not been on the staff there and university professors also disputed her assertions, undercutting her frequent appearances n the media and her claims for international achievements and as she was just presented an achievement award by Greek Education Minister Niki Kerameus who said, Her passion for science inspires us and fills us with optimism.

A Facebook post by Costas Bouyioukos, assistant professor of bioinformatics at Paris Diderot University in France that went viral went even further in discrediting her as he said She is not even fit to be called a scientist for most people.

Bouyioukos said she only and only completed the space agencys Frontier Development Lab, an eight-week educational program.

Antoniadou, the inspiration for Greeces first Barbie doll, has been described as a specialist in the fields of regenerative medicine, artificial organ bioengineering and space medicine, as well as training astronauts at NASA, and working as CEO of Transplants Without Donors, which creates artificial organs for transplants, the paper said.

She has been called a Greek scientist of global calibre by Greek media and was voted 2013 Woman of the Year at the annual British FDM Everywoman in Technology Awards, winning the NASA-ESA Outstanding Researcher Award in 2012 which doesnt appear to be real and presiding over the European Health Parliament.

Greek Hoaxes, a team which debunks fake news, also dismissed her claim to have worked on a team that built the first trachea implant to be successfully used on a patient at University College London, saying the patient died afterwards, the paper reported.

She issued a statement on Facebook saying she was working on a project on artificial intelligence for NASA but would not comment to the paper while a spokesperson for the agency said she was not an employee there but couldnt say if she had worked as a sub-contractor on projects.

The National Herald earlier wrote of her achievements as well, saying that he had said of her motivation: Love another person, even when they lose themselves, when their hygiene is failing, when they dont eat, when they dont care if they are in the light or the darkness. When they have given up and you want to give them a kick and put them to bed. Love, even when youre not sure its worth it. Admire them, even if they look at you without actually seeing you.

She had said she was a researcher in the interdisciplinary fields of regenerative medicine and bioastronautics, specializing in the regeneration of artificial organs from stem cells as an alternative therapeutic pathway for transplants and worked on the creation of cerebral implants, artificial skin, muscles, ears, nerves and the esophagus.

She said she designed a series of bioreactors and tissue engineering tools and has created the worlds first amniotic fluid stem cell bank, conducted experimental studies on the development of bio-nanotubes as drug carriers for targeted cancer therapies, as well as clinical trials for stem cell therapies for lung cancer.

Antoniadou also said she was on the Advisory Committee of the Research and Analysis Organization, DIANEOSIS, in Greece and had been honored by the European Patent Organization in Germany but there were no reports in the wake of others challenging her background whether any of what she said she had done was true.

Read the original here:
Greek Woman's Claim to Be Scientist Refuted by NASA - The National Herald